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ABSTRACT
Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder that has no cure,
no therapies to stop the disease progression, and limited palliative care options. As the
6th leading cause of death in the United States, it is necessary to discover therapeutics
which can alter disease progression to alleviate the burden on patients, caregivers, and
healthcare systems. In the search of therapeutics for AD, dietary polyphenols have
become the topic of research as epidemiological evidence suggests that exposure to
dietary polyphenols, such as a Mediterranean diet, over one’s life, reduces the risk of
dying from AD. Additionally, evidence from rodent models of AD suggests that dietary
polyphenols can reduce the severity of cognitive decline and attenuate
neuroinflammation, which is thought to be a contributing factor to disease progression.
Because of these findings, several dietary polyphenols have entered the clinic in an
attempt to elucidate their potential beneficial effects. For example, curcumin, from the
curry spice turmeric (Curcuma longa), and resveratrol, a phytoalexin stilbene found in
a variety of plants, have been investigated in AD disease populations in phase I and II
clinical studies. However, these agents have only had moderate to little success which
increases the demand for novel dietary polyphenols leads that may have potentially
beneficial effects in the treatment of AD. Due to this demand, this dissertation
investigates novel polyphenols and gut metabolites of dietary polyphenols from a
variety of dietary sources for potential efficacy in a Caenorhabditis elegans (C. elegans)
model of AD. This dissertation also employs molecular biology and mass spectrometry
techniques to elucidate the potential mechanisms of action of select compounds found
to be efficacious in a C. elegans model of AD. Finally, a polyphenol-enriched extract

was evaluated in a murine model of AD for the potential to reduce neuroinflammation
when administered orally.
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SATEMENT OF THE PROBLEMS
Alzheimer’s disease poses a substantial risk to human health, a risk that is growing
steadily as the population ages. Nevertheless, few reliable treatments exist to slow the
progression of, mitigate symptoms, or cure this disease. In recent years, dietary
polyphenols have been evaluated for their therapeutic potential. These compounds
have been shown to reduce inflammation, disaggregate amyloid deposits, and reduce
hyperphosphorylated tau. In animal models of Alzheimer’s disease, polyphenols have
shown to reverse the cognitive deficits associated with the disease. An emerging field
in the area of polyphenol research is the potential therapeutic benefit of gut microbiota
metabolites of polyphenols. Given the chemical nature of polyphenols, their
penetration across the blood-brain barrier is limited. However, gut microbiota
metabolites undergo several methylation, dehydroxylation and various other catabolic
reactions which increases the likelihood of blood-brain barrier penetration due to
reduced polarity and molecular weight. Herein, this dissertation describes the
identification of potential therapeutics from dietary polyphenols and gut microbiota
metabolism of these polyphenols, the mechanisms of action responsible for these
natural products’ potentially beneficial effects, and the efficacy of one of these
potential therapeutics in an animal model of Alzheimer’s disease.

xviii

CHAPTER 1

EFFICACY OF DIETARY POLYPHENOLS AND GUT METABOLITES IN A
CAENHORBADITIS ELEGANS MODEL OF ALZHEIMER’S DISEASE AND
INFLAMMATION
Manuscript 1 appears as published:
Isolation, identification, and biological evaluation of phenolic compounds from a
traditional North American confectionary, maple sugar. Liu, Yougqiang. Rose,
Kenneth N.; DaSilva, Nicholas A.; Johnson, Shelby L.; Seeram, Navindra P. (2017)
Journal of Agricultural and food chemistry. 65, 4289-4295.
Manuscript 2 appears as published:
Development of a neuroprotective potential algorithm for medicinal plants. Liu,
Weixi; Ma, Hang; DaSilva, Nicholas, A.; Rose, Kenneth N.; Johnson, Shelby L.;
Zhang, Lu; Wan, Chunpeng; Dain, Joel A.; Seeram, Navindra, Seeram P. (2016).
Neurochemistry International. 100, 164-177.
Manuscript 3 appears as published:
Phenolic compounds isolated and identified from Amla (Phyllanthus emblica) juice
powder and their antioxidant and neuroprotective activities. Rose, Kenneth N.; Wan,
Chunpeng; Thomas, A; Seeram, Navindra P.; Ma, Hang. (2018). Natural Product
Communications. 13, 1309-1311.
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ABSTRACT
Dietary polyphenols and gut microbial metabolites of dietary polyphenols offer a
diverse and large library of compounds that are potentially beneficial for the treatment
of neurodegenerative diseases, which potentially increases the likelihood of an
effective compound to be discovered and exploited clinically. This also offers a
significant scientific challenge. With such a vast library to search, there must be
efficient methods of determining which compounds should be further investigated and
which should be discarded as not relevant to the study. Herein, this chapter describes
the use of wild-type and a transgenic C. elegans model, which expressed the human bamyloid3-42 gene, to evaluate polyphenols and gut microbial metabolites derived from
a variety of plant sources.
The sources of polyphenols and their gut microbial metabolites used in this chapter are
from three plants that have been identified as being potentially beneficial for the
treatment of neurodegenerative diseases. The first is a maple syrup as an standardized,
phenolic-extract of maple syrup has recently been demonstrated to reduce
neuroinflammation markers in human SH-SY5Y neuroblastomas and reduced the
LPS-induced inflammation in murine BV-2 microglia.
The second is an extract from the fruit of Punica granatum (Pomegranate) as previous
work has demonstrated that the extract can attenuate hydrogen peroxide-induced
toxicity in murine microglia BV-2. Furthermore, pomegranate ellagitannins are known
to be the parent compound of the gut microbial metabolites urolithins. Previous
research has identified that urolithin treatment increases the lifespan of CL4176 C.
elegans and improves cellular respiration and induce mitophagy leading to overall
improved mitochondrial health.
2

The third is an extract from the fruit of Phyllanthus emblica (Amla or Indian
Gooseberry) as it is commonly used in the Ayurvedic system of traditional medicine.
The pure chemical constituents of the Indian Gooseberry plant are well known and
have been described as antioxidants. As with the pomegranate extract, the amla extract
contains ellagic acid and several ellagic acid derivates which are known to form
urolithins upon ingestion. The extract of Indian Gooseberry has been identified as
being potentially neuroprotective based on its antioxidant properties and its ability to
reduced β-amyloid fibrillization.
This chapter describes the investigation of these sources of natural products for their
potentially efficacious effects involved treating C. elegans with the various
compounds and extracts in their growth media and examining differences in survival
rates over time.
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MANUSCRIPT 1
Manuscripts 1 appears as published in the Journal of Agriculture and Food Chemistry.

Isolation, identification, and biological evaluation of phenolic compounds from a
traditional North American confectionary, maple sugar. Liu, Yougqiang. Rose,
Kenneth N.; DaSilva, Nicholas A.; Johnson, Shelby L.; Seeram, Navindra P. (2017)
Journal of Agricultural and Food Chemistry. 65, 4289-4295.
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Abstract
Maple sap, collected from the sugar maple (Acer saccharum) tree, is boiled to produce
the popular plant-derived sweetener, maple syrup, which can then be further
evaporated to yield a traditional North American confectionery, maple sugar.
Although maple sap and maple syrup have been previously studied, the phytochemical
constituents of maple sugar are unknown. Herein, 30 phenolic compounds, 1−30,
primarily lignans, were isolated and identified (by HRESIMS and NMR) from maple
sugar. The isolates included the phenylpropanoid-based lignan tetramers
(erythro,erythro)-4″,4‴-dihydroxy-3,3′,3″,3‴,5,5′-hexamethoxy-7,9′;7′,9-diepoxy4,8″;4′,8‴-bisoxy-8,8′-dineolignan-7″,7‴,9″,9‴-tetraol, 29, and (threo,erythro)-4″,4‴dihydroxy-3,3′,3″,3‴,5,5′-hexamethoxy-7,9′;7′,9-diepoxy-4,8″;4′,8‴-bisoxy-8,8′dineolignan-7″,7‴,9″,9‴-tetraol, 30, neither of which have been identified from maple
sap or maple syrup before. Twenty of the isolates (selected on the basis of sample
quantity available) were evaluated for their potential biological effects against
lipopolysaccharide-induced inflammation in BV-2 microglia in vitro and jugloneinduced oxidative stress in Caenorhabditis elegans in vivo. The current study
increases scientific knowledge of possible bioactive compounds present in maplederived foods including maple sugar.

5

1.0 Introduction
Maple syrup and maple sugar are traditional North American sweeteners commercially
produced only in eastern North America, predominantly in the province of Quebec in
Canada. They are obtained by boiling the sap collected from the sugar maple (Acer
saccharum) species which is endemic to this part of the world. Maple syrup is obtained
by boiling sap (approx. 40 L sap yields 1 L of syrup) and on further slow evaporation,
under low heat, yields the crystallized maple sugar product (1 L of syrup yields ca. 950
g of sugar). In the seventeenth and eighteenth centuries, maple sugar was an important
economic and political weapon in the fight to abolish slavery since cane sugar was
associated with slave labor.1 Nowadays, it is highly regarded as a specialty natural
sweetener and confectionery with the characteristic flavor and odor of pure maple syrup
which is highly desired by many consumers. Moreover, similar to maple syrup, maple
sugar is of significant cultural and economic importance to this region of the world.
Over recent years, a number of chemical compositional and biological studies
have been conducted on maple-derived food products, namely, maple sap (functional
beverage applications)2, maple syrup (food/sweetener applications),3-10 and maple
syrup-derived extracts (nutraceutical/functional food applications).11-19 Notably, maple
syrup and its derived extracts and pure compounds have been reported to show a wide
range of biological effects in vitro and in vivo including antioxidant, anti-inflammatory,
anticancer, antidiabetic, and neuroprotective properties.11-21 Therefore, given these
promising data as well as the worldwide popularity and consumption of maple-derived
food products, continued research to increase scientific knowledge of these natural
products is necessary.

6

Our laboratory has had an ongoing research program focused on the isolation,
identification, and biological evaluation of compounds from maple-derived foods.2-5,914,18-19

During these works, we reported on the isolation and structure elucidation (by

NMR) of sixty-three compounds, primarily phenolics, as well as inulin, from these
foods.2-5,10,13 Given that maple sugar has not been previously investigated, herein, our
objectives were: 1) isolate and identify the phytochemicals in maple sugar using a
combination of high resolution mass spectrometry (HRESIMS; by comparison to
authentic standards previously isolated by our laboratory) and nuclear magnetic
resonance (NMR; for those compounds for which we lacked authentic standards), and
2) evaluate the isolates for their effects against inflammation in murine BV-2
microglia in vitro and oxidative stress in Caenorhabditis elegans in vivo. This is the
first study to isolate, identify, and biologically evaluate the phytochemicals present in
maple sugar.

7

2.0 Materials and Methods
2.1 General Experimental Procedures
All nuclear magnetic resonance (1H and 13C NMR) were acquired on a Bruker 300
MHz instrument using deuterated methanol (CD3OD) as solvent. High resolution
electrospray ionization mass spectral (HRESIMS) data were acquired by direct
infusion of the pure compounds on a Triple TOF 4600 (Applied Biosystems/MDS
Sciex; Framingham, MA, USA) mass spectrometer equipped with a DuoSpray Ion
Source.
2.2 Chemicals
ACS grade ethyl acetate was obtained from Pharmco-AAPER through Wilkem
Scientific (Pawcatuck, RI, USA). The standards used for HRESIMS characterization
were previously isolated and identified (by NMR and HRESIMS) by our laboratory.2-5
MCI resin and LC-MS grades of acetonitrile and methanol were purchased from
Sigma-Aldrich (St. Louis, MO, USA). The C18 resin was purchased from Varian (Palo
Alto, CA, USA).
2.3 Maple sugar
Maple sugar (25 Kg) was produced by the Federation of Maple Syrup Producers of
Quebec (Longueil, Quebec, Canada) as previously reported by our laboratory.9
Briefly, maple syrup (containing < 1 % inverted sugar to ensure crystallization) was
slowly heated in baking pans (22-24°C) which were then cooled on a cold surface (ca.
1 min per L) followed by immersion in cold water (for 2-5 min) to promote formation
of the sugar crystals. As soon as crystals started to form, the mixture was stirred with a
mechanical mixer by continuously scraping the bottom and sides of the pan until the

8

temperature dropped to below 32°C. Once stirring was completed, the maple sugar
crystals were sieved to desired particle size.
2.4 Isolation of compounds 1-30 from maple sugar
Maple sugar (1250 g) was dissolved in DI water (2.5 L) and extracted with ethyl
acetate (3 x 2.5 L) at room temperature. The combined ethyl acetate extracts were
concentrated under reduced pressure in vacuo to yield a dried maple sugar ethyl
acetate extract (463 mg). The maple sugar ethyl acetate extract (463 mg) was initially
purified by C18 resin medium pressure liquid column chromatography (glass column:
350 mm in height and 50 mm in diameter) by eluting with a gradient solvent system of
5%, 15%, 30%, 40%, 50%, 60%, 80%, and 100% of MeOH:H2O to yield nine
fractions, A-I, respectively. Fractions A-F were further individually purified by MCI
resin column chromatography (glass column: 305 mm in height and 25 mm in
diameter) using gradient solvent systems of MeOH:H2O to yield compounds 1-30 as
follows. Fraction A afforded compound 1 (0.1 mg); fraction B afforded compounds 2
(0.5 mg), 3 (1.0 mg), 4 (0.1 mg), 5 (0.1 mg), 6 (0.1 mg), 7 (0.1 mg), 8 (0.7 mg), 9 (1.1
mg), 10 (0.2 mg) and 11 (0.5 mg); fraction C afforded compounds 12 (1.0 mg), 13 (1.1
mg), 14 (4.6 mg), 15 (1.2 mg), 16 (3.8 mg), 17 (0.9 mg), 18 (0.4 mg) and 19 (1.0 mg);
fraction D afforded compounds 20 (1.1 mg), 21 (0.7 mg), 22 (0.9 mg) and 23 (0.9
mg); fraction E afforded compounds 24 (0.8 mg), 25 (1.5 mg), 26 (0.5 mg), 27 (1.2
mg) and 28 (1.2 mg); and fraction F afforded compounds 29 (0.2 mg) and 30 (0.2 mg).
2.5 Identification of compounds 1-30 from maple sugar
Our laboratory has previously isolated and identified (by NMR and HRESIMS) sixtythree compounds from maple sap, maple syrup, and maple syrup-derived extracts.2-5,13
Therefore, using these authentic standards, compounds 1-28 were identified by
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HRESIMS (see Figure 1). Compounds 29 and 30, which were not previously isolated
from these aforementioned maple-derived foods, were identified by NMR and
HRESIMS (see below).
Compound 29: (-) HRESIMS, m/z 809.3026 [M-H]-, calcd. for molecular formula
C42H50O16; 1H-NMR (CD3OD, 300 MHz) δ 3.24 (m, H-8, 8'), 3.36 (m, H-9''b, 9'''b),
3.61 (m, H- 9''a, 9'''a), 3.84 (s, OCH3-3'', 3''', 5'', 5'''), 3.85 (s, OCH3-3, 5, 3', 5'), 3.87
(m, H-9b, 9'b), 3.91 (m, H-8''b, 8'''b), 4.30 (m, H-9a, 9'a), 4.78 (m, H-7, 7'), 4.90 (m,
H-7'', 7'''), 6.70 (s, H-2, 6, 2', 6'), 6.74 (brs, H-6'', 6'''), 6.79 (brs, H-5'', 5'''), 6.99 (brs,
H-2'', 2'''); 13C-NMR (CD3OD, 75 MHz) δ 55.7 (C-8, 8'), 56.3 (OCH3-3'', 3''', 5'', 5'''),
56.7 (OCH3-3, 3', 5, 5'), 61.7 (C-9'', 9'''), 73.1 (C-9, 9'), 74.1 (C-7'', 7'''), 87.2 (C-7, 7'),
104.3 (C-2, 6, 2', 6'), 111.4 (C-2'', 2'''), 115.6 (C-5'', 5'''), 120.7 (C-6'', 6'''), 133.8 (C-1'',
1'''), 136.1 (C-4, 4'), 138.9 (C-1, 1'), 146.9 (C-4'', 4'''), 148.6 (C-3'', 3'''), 154.5 (C-3, 5),
154.5 (C-3', 5').22
Compound 30: (-) HRESIMS, m/z 809.3053 [M-H]-, calcd. for molecular formula
C42H50O16; 1H-NMR (CD3OD, 400 MHz) δ 3.24 (m, H-8, 8'), 3.34 (m, H-9'''b), 3.45
(m, H-9''b), 3.68 (m, H-9'''a), 3.83 (s, OCH3-3''', 5'''), 3.84 (s, OCH3-3'', 5''), 3.85 (m,
H-9''a), 3.88 (s, OCH3-3, 5), 3.89 (s, OCH3-3', 5'), 3.93 (m, H-9b, 9’b), 3.96 (m, H8'''), 4.11 (m, H-8''), 4.29 (m, H-9a, 9'a), 4.78 (m, H-7, 7'), 4.99 (brs, H-7'', 7'''), 6.71
(brs, H-2, 6, 2', 6'), 6.74 (brs, H-5'', 5'''), 6.87 (brs, H-6'', 6'''), 6.99 (brs, H-2'', 2'''). 13CNMR (CD3OD, 75 MHz) δ 55.7 (C-8, 8'), 56.3 (OCH3-3'', 3''', 5'', 5'''), 56.7 (OCH3-3,
3', 5, 5'), 61.7 (C-9''), 61.8 (C-9'''), 73.0 (C-9, 9'), 74.0 (C-7''), 74.3 (C-7'''), 87.2 (C-7,
7'), 87.3 (C-8''), 88.7 (8'''), 104.2 (C- 2', 6'), 104.3 (C- 2, 6), 111.4 (C-2''), 111.6 (C2'''), 115.6 (C-5'') 115.8 (C- 5'''), 120.1 (C-6''), 120.7 (C-6'''), 133.5 (C-1''), 133.8 (C-
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1'''), 136.1 (C-4), 136.7 (C-4'), 138.9 (C-1), 139.1 (C-1'), 146.8 (C-4''), 147.1 (C-4'''),
148.7 (C-3''), 148.7 (C-3'''), 154.3 (C-3', 5'), 154.5 (C-3, 5).22
2.5 Analytical High Performance Liquid Chromatography with Diode Array
Detection (HPLC-DAD)
HPLC-DAD analyses were performed on a Hitachi Elite LaChrom system
(Pleasanton, CA, USA) consisting of a L2130 pump, a L-2200 autosampler, and a L2455 Diode Array Detector, operated by EZChrom Elite software. Chromatographic
separation was performed on a Waters Sunfire C18 column (250 mm × 4.6 mm i.d., 5
μm, Waters, Massachusetts, U.S.A.) with a Waters Sunfire C18 VanGuard PreColumn (20 mm × 4.6 mm i.d., 5 μm, Waters, Massachusetts, U.S.A.). The mobile
phase consisted of 0.1% (v/v) formic acid/ water (A) and methanol (B), with a
gradient elution at room temperature as follow: 0-5 min, 5% B; 5-165 min, from 5% to
53% B; 165-212 min, from 53% to 100% B; 212-224 min, 100% B. The flow rate was
at 1.0 mL/min, the injection volumes were 20 μL, and the detection wavelength was
280 nm.
2.6 Ultra-Fast Liquid Chromatography Mass Spectrometry (UFLC-ESI-TOFMS)
UFLC-ESI-TOF-MS analyses were performed on a SHIMADZU Prominence UFLC
system (Marlborough, MA, USA) consisting of two LC-20AD pumps, a DGU-20A
degassing unit, SIL-20AC auto sampler, CTO-20AC column oven and CBM-20A
communication bus module. Chromatographic separation was performed on a Waters
XBridge® BEH C18 column (100 mm × 2.1 mm i.d., 2.5 μm. Milford, MA, USA). The
mobile phase consisted of 0.1% (v/v) formic acid:acetonitrile (solvent A) and 0.1%
(v/v) formic acid:H2O (solvent B) with a gradient elution of 3-27% A from 0-96 min,
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27-97% A from 96-97 min, and 97% A from 97-110 min. The column temperature
was 40 °C, flow rate was 0.2 mL/min, and injection volume was 4 μL. Mass
spectrometry was performed using a Triple TOF 4600 system from Applied
Biosystems/MDS Sciex (Framingham, MA, USA) coupled with an electrospray
ionization (ESI) interface. Nitrogen was used in all cases. In this study, the parameters
were optimized as follows: ESI voltage, -4500 V; nebulizer gas, 40; auxiliary gas, 60;
curtain gas, 30; turbo gas temperature, 600°C; declustering potential, -70V. Instrument
calibration was carried out according to the manufacturer’s instructions. The mass
range was set from m/z 100 to 1000 and the mass range for product ion scan was m/z
100-1000. The data were acquired and processed using Analyst TF 1.7 Software.
2.7 Sample preparation for HPLC-DAD and UFLC-ESI-TOF-MS analyses
The maple sugar ethyl acetate extract (20 mg) was dissolved in 4 mL 60% aqueous
methanol (LC-MS grade). The solution was stored at 4 °C and filtered (0.22 micron
filter) before analyses.
2.8 Isolates for bioassays
Based on availability of the pure compounds isolated from maple sugar (obtained in
quantities > 0.5 mg), we evaluated twenty-one of the thirty isolates as follows: 2, 3, 8,
9, 11-17, 19- 28.
2.9 Cell culture conditions
Murine BV-2 microglia were a kind gift from Dr. Grace Sun (University of Missouri,
Columbia, MO, USA). The cells were cultured in DMEM (Life Technologies, Grand
Island, NY, USA) supplemented with 10% Fetal Bovine Serum (Gibco, Grand Island,
NY, USA) and penicillin/ streptomycin antibiotics (1%) (Gibco, Grand Island, NY,
USA). Cells were cultured and allowed to incubate within a humidified chamber at
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approximately 37°C under 5% CO2. Prior to seeding, cells were examined for their
viability and counted using trypan blue staining and a hemocytometer.
2.10 Anti-inflammatory assay (by measuring nitric oxide release with the Griess
reagent)
The murine BV-2 microglia cells were cultured as previously described by our
laboratory.18 In brief, microglia were seeded into 24-well plates at a density of
approximately 100,000 cells/mL. Cells were serum starved after following a 24 h
incubation period to ensure adherence. Cells were then exposed to either pure
compounds (at 10 μM), the positive control, resveratrol (RESV; at 10 μM), or vehicle
control for 1 hr. Lipopolysaccharide (LPS; at a concentration of 1 μg/mL) was then
added directly to the cells and allowed to incubate for 23 hours. Following this
incubation period, the total nitric oxide released into cell culture media was quantified
using the Greiss Reagent System (Promega, Madison, WI, USA).
2.11 Caenorhabditis elegans maintenance
Wild-type (N2) Caenorhabditis elegans were obtained from the Caenorhabditis
Genetics Center (CGC) at the University of Minnesota (Minneapolis, MN, USA).
Worm cultures were maintained on Nematode Growth Medium (NGM) (1.7% Agar,
0.3% NaCl, 0.25% peptone, 1 mM CaCl2, 1 mM MgSO4, 5 mg/L cholesterol in
ethanol, and 2.5 mM KPO4) in petri dishes at 20°C with UV-killed OP50 Escherichia
coli as a food source. Age synchronous cultures were obtained by the standard
hypochlorite method as previously reported by our laboratory.18 For sample treatment,
C. elegans were washed from their plates with liquid nematode growth medium (0.3%
NaCl, 0.25% peptone, 1 mM CaCl2, 1 mM MgSO4, 5 mg/L cholesterol in ethanol, and
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2.5 mM KPO4) and transferred to culture flasks containing UV-killed OP50 E. coli as
a food source.
2.12 Caenorhabditis elegans oxidative stress resistance assay
To determine if oxidative stress resistance is improved in C. elegans, a method to
induce oxidative stress was adapted as previously reported with minor modifications.23
Briefly, age synchronous culture of N2 (L2) worms in liquid NGM were transferred
into the wells of a 96-well plate. To each individual well, compounds were added to
achieve a final concentration of 10 µM. A solvent control well was made by adding
DMSO/water solution to achieve a final DMSO concentration of 0.01%. The cultures
were incubated in the dark for 24 h. After incubation with the compounds, the cultures
were exposed to 400 µM of 5-hydroxy-1,4-napthoquinine (also known as juglone).
Immediately after the addition of juglone, a baseline count was taken with a dissecting
microscope after which the worms were counted every hour for 6 hours.
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3.0 Results and Discussion
3.1 Isolation and identification of compounds in maple sugar
Our laboratory has conducted extensive studies on maple sap and maple syrup which
has led to the isolation and identification (by NMR) of sixty-three compounds,
predominantly phenolics, belonging to the lignan sub-class.2-5,13 Given our group’s
access to these authentic maple standards (many of which are not commercially
available), we initially compared the HPLC-DAD profiles of the ethyl acetate extracts
of maple syrup and maple sugar. As expected, there were marked similarities in the
chromatograms of maple syrup and maple sugar suggesting that the phenolic
compounds present in maple syrup were preserved in the slow heating evaporation
process required for its transformation to maple sugar. This was in support of our
previous findings where we reported that the natural phenolic compounds present in
maple sap are also preserved in the intensive heating/boiling process required in its
transformation to maple syrup.2 Thus, while flavor/odor compounds are created during
the cooking/boiling process of transforming maple sap to maple syrup, it was apparent
that the majority of the phenolic compounds originally present in the xylem sap of the
maple tree persist in maple syrup and maple sugar.
In our previous research projects on maple sap and maple syrup, 2-5,13 we obtained
the majority of the isolates in limited quantities which have since been exhausted
thereby hampering their evaluation in bioassays. Therefore, although we did not seek to
‘comprehensively re-isolate’ all of the compounds in maple sugar, we were able to
isolate (using chromatography) and identify (using HRESIMS and NMR) thirty (1-30)
of its constituents from a maple sugar ethyl acetate extract. Figure 1 shows the total ion
chromatography (TIC) of the maple sugar ethyl acetate extract with the accompanying
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identities of compounds 1-30 shown in Table 1 and their structures shown in Figure 2.
It should be noted that compounds 1-28 were identified by HRESIMS (by comparison
with authentic standards previously isolated by our laboratory2-5,13) while compounds 29
and 30 (for which we lacked authentic standards) were identified by NMR (further
described below).
Thus, based on retention times (tR) and accurate m/z of pseudo molecular ions (by
comparison to authentic standards), compounds 1-28 were identified as 2,3-dihydroxy1-(3,4-dihydroxyphenyl)-1-propanone (1), C-veratroylglycol (2), 2,3-dihydroxy-1-(4hydroxy-3,5-dimethoxyphenyl)-1-propanone (3), (erythro,erythro)-1-[4-(2-hydroxy-2(4-hydroxy-3-methoxyphenyl)-1-(hydroxymethyl)ethoxy)-3-methoxyphenyl]-1,2,3propanetriol

(4),

1,2-diguaiacyl-1,3-propanediol

(5),

(erythro,erythro)-1-[4-[2-

hydroxy-2-(4-hydroxy-3-methoxyphenyl)-1-(hydroxymethyl)ethoxy]-3,5dimethoxyphenyl]-1,2,3-propanetriol (6), epicatechin (7), (threo,erythro)-1-[4-[2hydroxy-2-(4-hydroxy-3-methoxyphenyl)-1-(hydroxymethyl)ethoxy]-3,5dimethoxyphenyl]-1,2,3-propanetriol

(8),

3-hydroxy-1-(4-hydroxy-3,5-

dimethoxyphenyl)propan-1-one (9), coumaric acid (10), leptolepisol D (11),
guaiacylglycerol-β-O-4'-coniferyl

alcohol

(12),

lyoniresinol

(13),

threo-

guaiacylglycerol-β-O-4'-dihydroconiferyl alcohol (14), isolariciresinol (15), erythroguaiacylglycerol-β-O-4'-dihydroconiferyl

alcohol

(16),

[3-[4-[(6-deoxy-α-L-

mannopyranosyl)oxy]-3-methoxyphenyl]methyl]-5-(3,4-dimethoxyphenyl)-dihydro-3hydroxy-4-(hydroxymethyl)-2(3H)-furanone

(17),

erythro-1-(4-hydroxy-3-

methoxyphenyl)-2-[4-(3-hydroxypropyl)-2,6-dimethoxyphenoxy]-1,3-propanediol
(18),

5-(3'',4''-dimethoxyphenyl)-3-hydroxy-3-(4'-hydroxy-3'-methoxybenzyl)-4-

(hydroxymethyl)dihydrofuran-2-one (19), secoisolariciresinol (20), icariside E4 (21),
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sakuraresinol (22), dehydroconiferyl alcohol (23), syringaresinol (24), acernikol (25),
2-[4-[2,3-dihydro-3-(hydroxymethyl)-5-(3-hydroxypropyl)-7-methoxy-2benzofuranyl]-2,6-dimethoxyphenoxy]-1-(4-hydroxy-3-methoxyphenyl)-1,3propanediol

(26),

(1S,2R)-2-[2,6-dimethoxy-4-[(1S,3aR,4S,6aR)-tetrahydro-4-(4-

hydroxy-3,5-dimethoxyphenyl)-1H,3H-furo[3,4-c]furan-1-yl]phenoxy]-1-(4-hydroxy3-methoxyphenyl)-1,3-propanediol (27) and buddlenol E (28). Since we lacked
authentic standards for compounds 29 and 30, they were identified as two di-lignans by
NMR data (provided in the Methods section) as (7R,7'R,7''S,7'''S,8S,8'S,8''S,8'''S)-4'',4'''dihydroxy-3,3',3'',3''',5,5'-hexamethoxy-7,9';7',
dineolignan-7'',7''',9'',9'''-tetraol

(29)

and

dihydroxy-3,3',3'',3''',5,5'-hexamethoxy-7,9';7',

9-diepoxy-4,8'';4',8'''-bisoxy-8,8'(7R,7'R,7''R,7'''S,8S,8'S,8''S,8'''S)-4'',4'''9-diepoxy-4,8'';4',8'''-bisoxy-8,8'-

dineolignan-7'',7''',9'',9'''-tetraol (30). The NMR data of these di-lignans were in
agreement with published values.22 Whilst this is the first report of these di-lignans in a
maple-derived food product, given that these are naturally occurring plant secondary
metabolites, it is highly likely that they are also present in maple sap and maple syrup
but were not isolated/obtained in our previous studies. 2-5,13 As shown in the HPLC-DAD
chromatograms of maple syrup and maple sugar, there are many minor peaks present in
these foods and obtaining all of these compounds is not possible due to a variety of
reasons including complicated matrix with multiple overlapping peaks, low yields of
isolates, etc. Nevertheless, overall, similar to our previous observations for maple sap
and maple syrup, 2-5,13 the majority of the phenolic compounds found in maple sugar are
also lignans.
3.2 Evaluation of anti-inflammatory effects of maple sugar compounds in murine
BV-2 microglia
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Our group has previously utilized a murine BV-2 microglia cell model to evaluate the
anti-inflammatory effects of a phenolic-enriched maple syrup extract.18 However, as
previously mentioned, because of limited sample quantities available, the pure maple
compounds were not assayed in that study. Therefore, herein, the BV-2 murine
microglia were pre-treated with twenty-one of the maple sugar isolates (obtained > 0.5
mg), namely, compounds 2, 3, 8, 9, 11-17, and 19- 28 (at 10 µM) for one hour (Figure
3A). Resveratrol (RESV; at 10 and 20 μM) was used as a positive control since this
natural polyphenol is well-known for its anti-inflammatory properties.18 Immediately
following pre-treatment with the compounds, lipopolysaccharide (LPS) was added to
stimulate the production of nitric oxide (NO). Total NO concentrations found in cell
culture media of LPS-treated cells were approximately 33.85 μM ± 0.23 as compared to
vehicle treated cells which released approximately 0.69 μM ± 0.04 of NO. RESV
produced significantly lower NO media levels by approximately 16.36% (28.31 μM
±0.33) and 33.76% (22.42 μM ± 0.05) at 10 and 20 μM respectively (Figure 3A).
Among the isolates, compounds 3, 8, 9, 17, and 24 significantly decreased NO levels as
follows 9.89% (30.5 μM ± 0.14), 18.52% (27.58 μM ±0.72), 4.99% (32.16 μM ± 0.23),
4.96% (32.17 μM ± 0.41) and 9.57% (30.61μM ± 0.84), respectively (Figure 3B). Based
on this data, it is not possible to make any structure activity related (SAR) inferences
given the structural diversity of the compounds.
3.3 Evaluation of effects of maple sugar isolates on oxidative stress in
Caenorhabditis elegans in vivo
Natural products, including resveratrol, have been shown to improve oxidative stress
resistance and life span in Caenorhabditis elegans after exposure to the pro-oxidant,
juglone.23,24 Therefore, using this in vivo model, Kaplan-Meier survival curves were
18

generated for the twenty-one maple sugar isolates and their Mantel-Haenszel Ratio
(MHR) are listed in Table 3. Nine of the twenty-one compounds extended lifespan of
C. elegans in a high-oxidative stress environment by a statistically significant margin
(P< 0.01), namely, 16, 17, 20-24, 26, and 28 indicating that these compounds were
mitigating the toxicity of juglone. Similar to the data accumulated from the in vitro BV2 cell assay, it is not possible to make any SAR inferences given the structural diversity
of the compounds.
In summary, this is the first study to isolate, identify, and biologically evaluate the
phytochemicals present in the traditional North American confectionery, maple sugar.
Similar to other maple-derived food products, maple sugar contains a variety of
phenolic compounds among which the lignan sub-class predominate. The protective
effects of the maple sugar isolates against inflammation (in BV-2 microglia in vitro)
and oxidative stress (in C. elegans in vivo) is in agreement with a vast body of
literature supporting similar effects for phenolic compounds found in plant foods.
Whether these biological effects are translatable in vivo would require animal studies
which is included in our group’s future planned studies.
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Figure 1. Total ion chromatogram (TIC) of maple sugar ethyl acetate extract.
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Figure 2. Compounds identified in maple sugar ethyl acetate extract.
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Figure 3. Anti-inflammatory effects of maple sugar isolates assayed by
measuring nitric oxide release by murine BV-2 microglia after exposure to
lipopolysaccharide (LPS). Fig. 3A BV-2 microglia were pretreated with twenty-one
isolates (10 μM), positive control, resveratrol (RESV; 10 and 20 μM) or vehicle
control (DMSO) for one hour prior to lipopolysaccharide (LPS) stimulation at 1
μg/mL for 23 hours. The total NO concentrations were assayed using the Greiss
Assay. Fig. 3B. At 10 μM, compounds 3, 8, 9, 17, and 24 and RESV significantly
decreased NO release as compared to the cells treated with LPS-alone. Statistical
significance as determined by student’s t-test was determined as follows p < 0.05 * ;
p< 0.01 ** ; p< 0.001 *** ; p< 0.0001 ****.
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Table 1. UFLC-ESI-TOF-MS data for compounds identified in maple sugar ethyl
acetate extract.

No
.
1
2

tR

Compounds
2,3-dihydroxy-1-(3,4-dihydroxyphenyl)-1-propanone
C-veratroylglycol

HR-ESI(-)-MS
-

Error

Molecular

(min)

[M-H] m/z exptl (theor)

(ppm)

formula

4.71

197.0462 (197.0455)

3.3132

C9H10O5

8.84

211.0621 (211.0611)

4.2773

C10H12O
5

3

2,3-dihydroxy-1-(4-hydroxy-3,5-dimethoxyphenyl)-1-

11.6

propanone
4

241.0727 (241.0717)

3.8912

6

(erythro,erythro)-1-[4-(2-hydroxy-2-(4-hydroxy-3-

13.2

methoxyphenyl)-1-(hydroxymethyl)ethoxy)-3-methoxyphenyl]-

C11H14O
6

409.1499 (409.1504)

-

C20H26O

1.2375

9

319.1190 (319.1187)

0.9019

C17H20O

439.1617 (439.1609)

1.6598

C21H28O

1

1,2,3-propanetriol
5

15.8

1,2-diguaiacyl-1,3-propanediol

3
6

(erythro,erythro)-1-[4-[2-hydroxy-2-(4-hydroxy-3-

17.9

methoxyphenyl)-1-(hydroxymethyl)ethoxy]-3,5-

6

9

10

dimethoxyphenyl]-1,2,3-propanetriol
7

22.7

epicatechin

289.0717 (289.0717)

2
8

(threo,erythro)-1-[4-[2-hydroxy-2-(4-hydroxy-3-

24.2

methoxyphenyl)-1-(hydroxymethyl)ethoxy]-3,5-

7

439.1624 (439.1609)

-

C15H14O

0.2142

6

3.2537

C21H28O
10

dimethoxyphenyl]-1,2,3-propanetriol
9

10

11

12

13

14

15

16

3-hydroxy-1-(4-hydroxy-3,5-dimethoxyphenyl)propan-1-one

25.4

2.0113

C11H14O

163.0408 (163.0400)

4.4910

C9H8O3

515.1941 (515.1922)

3.5496

C27H32O

375.1457 (375.1449)

2.0605

C20H24O

3
26.5

coumaric acid

225.0773 (225.0768)

5

7
30.5

leptolepisol D

9
39.9

guaiacylglycerol-β-O-4′-coniferyl alcohol

10

1
40.4

lyoniresinol

7

419.1727 (419.1711)

3.7173

C22H28O

377.1606 (377.1605)

0.0608

C20H26O

0

threo-guaiacylglycerol-β-O-4′-dihydroconiferyl alcohol

42.3
0
43.9

isolariciresinol

8

7

359.1504 (359.1500)

1.0793

C20H24O

377.1609 (377.1605)

0.8562

C20H26O

9

erythro-guaiacylglycerol-β-O-4′-dihydroconiferyl alcohol

27

44.7
2

6

7

17

[3-[4-[(6-deoxy-α-L-mannopyranosyl)oxy]-3-

50.9

methoxyphenyl]methyl]-5-(3,4-dimethoxyphenyl)-dihydro-3-

[M-H+HCOOH]-

4.1499

C27H34O

0

595.2057 (595.2032)

52.2

407.1720 (407.1711)

2.1077

C21H28O

403.1409 (403.1398)

2.6253

C21H24O

12

hydroxy-4-(hydroxymethyl)-2(3H)-furanone
18

erythro-1-(4-hydroxy-3-methoxyphenyl)-2-[4-(3hydroxypropyl)-2,6-dimethoxyphenoxyl]-1,3-propanediol

19

5-(3′′,4′′-dimethoxyphenyl)-3-hydroxy-3-(4′-hydroxy-3′methoxybenzyl)-4-(hydroxymethyl)dihydrofuran-2-one

20

21

2
52.8
1
54.7

secoisolariciresinol

23

24

25

26

8

361.1655 (361.1656)

5

icariside E4

56.8
9

22

8

sakuraresinol

60.1

dehydroconiferyl alcohol

[M-H+HCOOH]-

0.4497

6

4.1714

C26H34O

551.2157 (551.2134)
[M-H+HCOOH]-

0

509.2049 (509.2028)

60.5

359.1512 (359.1500)

10

4.0535

C24H32O

3.3068

C20H24O

9

8
69.5

syringaresinol

6

417.1566 (417.1554)

2.6567

C22H26O

585.2364 (585.2341)

3.8683

C31H38O

0
73.6

acernikol

8

0

2-[4-[2,3-dihydro-3-(hydroxymethyl)-5-(3-hydroxypropyl)-7methoxy-2-benzofuranyl]-2,6-dimethoxyphenoxy]-1-(4-

78.2

C20H26O

11

585.2360 (585.2341)

3.1848

7

C31H38O
11

hydroxy-3-methoxyphenyl)-1,3-propanediol
27

(1S,2R)-2-[2,6-dimethoxy-4-[(1S,3aR,4S,6aR)-tetrahydro-4-(4hydroxy-3,5-dimethoxyphenyl)-1H,3H-furo[3,4-c]furan-1-

82.4

613.2307 (613.2290)

2.6894

3

C32H38O
12

yl]phenoxy]-1-(4-hydroxy-3-methoxyphenyl)-1,3-propanediol
28

29

83.0

buddlenol E

583.2200 (583.2184)

2.5959

8

(7R,7'R,7''S,7'''S,8S,8'S,8''S,8'''S)-4'',4'''-dihydroxy-

91.6

3,3',3'',3''',5,5'-hexamethoxy-7,9';7',9-diepoxy-4,8'';4',8'''-bisoxy-

C31H36O
11

809.3048 (809.3026)

2.7062

5

C42H50O
16

8,8'-dineolignan-7'',7''',9'',9'''-tetraol
30

(7R,7'R,7''R,7'''S,8S,8'S,8''S,8'''S)-4'',4'''-dihydroxy-

96.4

3,3',3'',3''',5,5'-hexamethoxy-7,9';7',9-diepoxy-4,8'';4',8'''-bisoxy8,8'-dineolignan-7'',7''',9'',9'''-tetraol

28

0

809.3053 (809.3026)

3.3241

C42H50O
16

Table 2. Effects of maple sugar isolates on oxidative stress induced by exposure to
juglone in Caenorhabditis elegans Age synchronous C. elegans were treated with the
maple sugar isolates (10 µM) for 24 h after which the pro-oxidant, juglone was added
(400 µM). Living worms were counted every hour for six hours. Kaplan-Meier
survival curves were constructed using GraphPad Prism 7. The Mantel-Haenszel ratios
calculated from the curves were used as measures of statistical significance.
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Abstract
Medicinal plants are promising candidates for Alzheimer’s disease (AD) research but
there is lack of systematic algorithms and procedures to guide their selection and
evaluation. Herein, we developed an AD Neuroprotective Potential Algorithm (NPA)
by evaluating twenty-three standardized and chemically characterized Ayurvedic
medicinal plant extracts in a panel of bioassays targeting oxidative stress, carbonyl
stress, protein glycation, amyloid beta (Aβ) fibrillation, acetylcholinesterase (AChE)
inhibition, and neuroinflammation. The twenty-three herbal extracts were initially
evaluated for: 1) total polyphenol content (Folin-Ciocalteu assay), 2) free radical
scavenging capacity (DPPH assay), 3) ferric reducing antioxidant power (FRAP assay),
4) reactive carbonyl species scavenging capacity (methylglyoxal trapping assay), 5)
anti-glycative effects (BSA-fructose, and BSA-methylglyoxal assays) and, 6) anti-Aβ
fibrillation effects (thioflavin-T assay). Based on assigned index scores from the initial
screening, twelve extracts with a cumulative NPA score ≥ 40 were selected for further
evaluation for their: 1) inhibitory effects on AChE activity, 2) in vitro anti-inflammatory
effects on murine BV-2 microglial cells (Griess assay measuring levels of
lipopolysaccharide-induced nitric oxide species), and 3) in vivo neuroprotective effects
on Caenorhabditis elegans post induction of Aβ1-42 induced neurotoxicity and paralysis.
Among these, four extracts had a cumulative NPA score ≥ 60 including Phyllanthus
emblica (amla; Indian gooseberry), Mucuna pruriens (velvet bean), Punica granatum
(pomegranate) and Curcuma longa (turmeric; curcumin). These extracts also showed
protective effects on H2O2 induced cytotoxicity in differentiated cholinergic human
neuronal SH-SY5Y and murine BV-2 microglial cells and reduced tau protein levels in
the SH-SY5Y neuronal cells. While published animal data support the neuroprotective
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effects of several of these Ayurvedic medicinal plant extracts, some remain unexplored
for their anti-AD potential. Therefore, the NPA may be utilized, in part, as a strategy to
help guide the selection of promising medicinal plant candidates for future AD-based
research using animal models.
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1.0 Introduction
Alzheimer’s disease (AD) is a common neurodegenerative disorder characterized by the
progression of cognitive decline leading to severe dementia (Buckner et al., 2005). The
accumulation of senile plaques and neurofibrillary tangles in cerebral cortex and
hippocampus are two major pathological hallmarks of AD (Ittner and Götz, 2011).
However, due to the complexity of the disease, the precise factors which trigger the
development of AD remains unknown (Alzheimer’s Association, 2015). Moreover,
given the unclear etiology of AD, current therapeutic approaches focus mainly on
symptom management but no treatment is available to alter or reverse the course of the
disease (Alzheimer’s Association, 2015; Citron, 2010). Although the pathogenesis of
AD is still under investigation, increasing evidence suggest that AD is a multifactorial
disease which develops as a result of several risk contributors instead of a single cause
alone (Norton et al., 2014; Reitz and Mayeux, 2014).
Oxidative stress and the production of reactive oxygen species (ROS) have been
implicated in the pathogenesis of AD and are believed to be leading causative factors
for neuronal cell dysfunction and cell death (Lin and Beal, 2006; Smith et al., 2000). It
has been demonstrated that the products of protein oxidation and lipid peroxidation are
elevated in AD patients (Christen, 2000). In addition, in the AD brain, the activities of
antioxidant enzymes are altered, accompanied with a decline in the expression of these
antioxidant enzymes (Christen, 2000; Smith et al., 2000). Given the established links
between oxidative stress and AD, antioxidants, including those from natural products,
are extensively studied for their neuroprotective abilities and constitute dietary
intervention strategies for AD prevention and treatment (Alzheimer’s Association,
2015; Choi et al., 2012; Praticò, 2008).
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Apart from oxidative stress, carbonyl stress and the formation of advanced glycation
end-products (AGEs) resulting from protein glycation are also believed to be vital
contributors to AD (Srikanth et al., 2011; Vicente Miranda and Outeiro, 2010).
Glycation is one type of post-translational modification of proteins, resulting in the
formation of AGEs both intracellularly and extracellularly. Glycation and AGEs
formation are associated with AD due to several reasons. First, AGEs bind to the
transmembrane receptor, RAGE (receptor for AGEs), upregulate RAGE expression,
and activate RAGE-mediated neuronal dysfunction and neuron damages (Srikanth et
al., 2011). Second, RAGE mediates the transportation of beta amyloid (Aβ) across the
blood brain barrier (BBB) (Donahue et al., 2006). Therefore, the activation of RAGE
by AGE can cause Aβ accumulation in the brain. Third, during the course of glycation
and AGE formation, ROS and reactive carbonyl species (RCS) are generated as byproducts which, in turn, promote AGE formation and cause neurotoxicity (Ahmed et
al., 2005; Münch et al., 2012; Picklo et al., 2002). Consequently, all of the factors
involved in this positive feedback loop including AGEs, RCS, and ROS are considered
to be promising targets for AD prevention and treatment.
Another common target for AD therapy is the Aβ peptide which consists of 40 to 42
amino acids and is generated from the cleavage of the Aβ precursor protein. Aβ is the
major component of senile plaques and neurofibrillary tangles, two pathological
hallmarks of AD (Buckner et al., 2005; Palop and Mucke, 2010). In AD patients,
elevated Aβ levels were observed in both cerebrospinal fluid and blood (Mawuenyega
et al., 2010). In addition, certain forms of Aβ, including fibrillated Aβ and glycated Aβ
(Aβ-AGEs), have been shown to be neurotoxic (Butterfield, 2002; Koo et al., 1999; Li
et al., 2013). Fibrillated Aβ can induce neurotoxicity by enhancing neuronal oxidative
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stress and neuroinflammation (Butterfield, 2002; Koo et al., 1999). Aβ-AGEs can
induce intracellular oxidative stress and inflammation by activating RAGE and
upregulating RAGE expression in neuronal cells (Li et al., 2013). Therefore,
considerable research efforts have been directed to finding inhibitors which may prevent
or reverse the formation of Aβ fibrils and Aβ-AGEs. For example, aminoguanidine
(AG), a synthetic glycation inhibitor, can reduce glycated Aβ formation, attenuate
RAGE upregulation, and restore the cognitive deficit in AD animal models (Li et al.,
2013). However, AG failed in human clinical trials due to severe side effects
(Thornalley, 2003) leading to the search for non-toxic alternatives including medicinal
plants and their derived natural products and botanical extracts (Solanki et al., 2016;
Venigalla et al., 2016).
In addition to oxidative stress, glycation, and Aβ formation, neuroinflammation is
another pivotal factor implicated in the development of neurodegenerative diseases with
increased inflammation observed in AD (Eikelenboom et al., 2002). In addition,
inflammatory stress leads to the activation of microglia cells, the immune cells in the
central nervous system, which release nitric oxide species (NOS) including nitrates and
nitrites. These NOS are neurotoxic and cause massive neuronal death further
exacerbating neurodegenerative diseases (Eikelenboom et al., 2002; Eikelenboom et al.,
2006).
For centuries, traditional systems of medicines such as Ayurveda [from India, a country
which has one of the lowest incidences of AD worldwide (Chandra et al., 2001; Vas et
al., 2001)] and traditional Chinese medicine (TCM) (Steele et al., 2013), have used
medicinal plants to treat several ailments including neurodegenerative diseases. While
neurochemical/biological studies have been conducted on some these traditional
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medicinal plants, there is a lack of systematic procedures and algorithms to help guide
the selection and evaluation of the most promising candidates for further AD-based
research using animal models. This is urgently needed given the large variety of
medicinal plant species (and combinations thereof) used worldwide in the traditional
systems of medicines of various cultures. Furthermore, although medicinal plants are
consumed as foods, herbs, spices, beverages, and botanical extracts, their underlying
mechanisms of neuroprotective effects remain unclear. Therefore, given all of the
aforementioned factors, herein, we utilized a panel of bioassays including total
polyphenol contents, antioxidant capacities, anti-glycation effects, carbonyl scavenging
abilities, anti-Aβ fibrillation, acetylcholinesterase (AChE) inhibition, and antineuroinflammatory activities to develop a Neuroprotective Potential Algorithm (NPA)
to aid in the evaluation and selection of promising medicinal plant candidates for future
AD based research using pre-clinical animal models (see Figure 1). We selected
twenty-three commercially available and chemically characterized medicinal plant
extracts (see Table 1), commonly consumed as foods (in India, and elsewhere), and
used in Ayurveda, to develop the NPA.
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2.0 Materials and Methods
2.1. Chemicals
The herbal extracts are botanically authenticated and chemically standardized GRAS
(generally regarded as safe) extracts which are commercially available for human
consumption and sourced from a single reputable natural products supplier, namely,
Verdure Sciences (Noblesville, IN, USA), to ensure access to validated and consistent
samples. The Latin binomial and common names, as well as the traditional uses, of the
twenty-three medicinal plant species are provided in Table 1. Each extract was
dissolved in DMSO (20.0 mg/mL) and diluted to test concentrations (10-2000 μg/mL)
with 0.1 M phosphate buffer (pH=7.2). The following chemicals were purchased from
Sigma-Aldrich Chemical Co. (St. Louis, MO, USA): butylated hydroxytoluene (BHT),
bovine serum albumin (BSA), methylglyoxal (MGO), aminoguanidine hydrochloride
(AG), gallic acid, resveratrol (RESV), galanthamine, 1,2-phenylenediamine (PD), 2,3dimethylquinoxaline (DQ), 2,4,6-tripyridyl-s-triazine, iron (III) chloride hexahydrate,
L-ascorbic acid, HPLC-grade methanol and trifluoroacetic acid (TFA), thioflavin T
agent (ThT), Tris-HCl buffer (pH 8.0), acetylcholinesterase (AChE; from electric eel),
5,5′-dithiobis(2-nitrobenzoic acid) (DTNB), and acetylthiocholine iodide (ATCI).
Human beta amyloid 1-42 (Aβ1-42) peptide (Catalog #: AS-2027) was purchased from
Anaspec (San Jose, CA, USA).
2.2. Antioxidant assays
2.2.1. Free radical scavenging activity (DPPH assay)
The extracts were evaluated for their free radical scavenging capacity by the 2,2diphenyl-1-picrylhydrazyl (DPPH) assay as previously reported by our laboratory (Ma
et al., 2016). Briefly, 100 μL serial dilutions (10-2000 μg/mL) of each test sample were
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mixed with 100 μL of a 0.2 mM DPPH solution in a 96-well plate. After incubation at
room temperature for 30 min, sample absorbance was read (at 517 nm) using a
microplate reader (SpectraMax M2, Molecular Devices Corp., Sunnyvale, CA, USA).
2.2.2. Ferric reducing antioxidant power (FRAP assay)
The ferric reducing antioxidant power (FRAP) of the extracts were measured following
published methods (Maksimović et al., 2005; Tsai et al., 2002). The FRAP reagent
contained 100 mL acetate buffer (3 mM, pH 3.6), 10 mL 2,4,6-tripyridyl-s-triazine (10
mM) in 40 mM hydrochloric acid, and 10 mL FeCl3·6H2O (20 mM). Briefly, 1.5 mL
of freshly prepared FRAP reagent was mixed with 50 µL of each extract (final
concentration of 100 µg/mL) and the absorbance was measured at 593 nm after 5
minutes using an UltroSpec 2100 instrument (Biochrom Ltd, Cambridge, UK). Lascorbic acid (0.1 - 3 mM) was used as the positive control and to generate a calibration
curve. The FRAP capacity of each extract was expressed as ascorbic acid equivalents
(AAE)/mg where AAE is defined as follows: the reducing power of 1 mg dry plant
material is equivalent to the reducing power of 1 nM of L-ascorbic acid (Maksimović
et al., 2005). All data were the average of three individual experiments.
2.3. Total polyphenol content
The extracts were quantified for total phenolic content using the Folin–Ciocalteu
method and expressed as gallic acid equivalents (GAEs) as previously reported by our
laboratory (Jean-Gilles et al., 2012). Briefly, each sample (5 mg) was dissolved in 500
μL of 50% aqueous methanol, and 100 μL of each sample was incubated with 50 μL of
the Folin–Ciocalteu reagent for 5 min at room temperature. Then 150 μL of a 20%
sodium carbonate (Na2CO3) solution and 250 μL of distilled water were added to each
sample and the resulting solution was vortexed. The reaction mixtures were further
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incubated for 30 min at 40 °C and then immediately cooled to room temperature. The
standard (i.e. gallic acid) was prepared in parallel with the samples. Each sample was
centrifuged and 200 μL of supernatant was added to a 96-well plate and absorbance read
at 756 nm on a Spectramax plate reader (SpectraMax M2, Molecular Devices Corp.,
Sunnyvale, CA, USA).
2.4. BSA-fructose assay
The extracts were evaluated for their anti-glycation effects using the BSA-fructose assay
based on previously reported methods by our laboratory (Liu et al., 2014; Ma et al.,
2015). Briefly, 100 µg/mL of each extract was added to the glycation reaction mixture
containing 10 mg/mL BSA and 100 mM D-fructose and incubated at 37 °C for 21 days.
The intrinsic fluorescence of each sample was measured at excitation and emission
wavelengths of 360 nm and 435 nm, respectively. The synthetic anti-gycating agent,
aminoguanidine (AG), at an equivalent concentration of 100 µg/mL, served as the
positive control.
2.5. BSA-MGO assay
The extracts were evaluated for their inhibitory effects on carbonyl species induced
AGEs formation using a reaction model containing BSA (10 mg/mL), MGO (5 mM),
and sample (100 µg/mL) as previously reported by our laboratory (Sun et al., 2016).
Each sample was measured for intrinsic fluorescence after 7 days incubation at 37 °C
with excitation and emission wavelengths of 360 nm and 435 nm, respectively. The
aforementioned wavelengths were found optimal for the detection of MGO derived
AGEs. The positive control, AG, was evaluated at an equivalent concentration of 100
µg/mL.
2.6. MGO trapping assay
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The extracts were measured for their trapping capacity of RCS as previously reported
by our laboratory (Liu et al., 2014). Briefly, each reaction solution contained MGO (5
mM), and test sample (100 µg/mL), or the positive control, AG (1000 µg/mL), and the
mixtures were incubated at 37 °C for 4 hours. Afterwards, the derivatization reagent,
PD (20 mM), and internal standard, DQ (5 mM), in 0.1 M phosphate buffer, pH 7.2
were added to the reaction mixture, and the remaining MGO was quantified by HPLCDAD. The percentage decrease of MGO was calculated using the following equation:
MGO decrease % = [1 - (MGO amounts in solution with tested sample/MGO amounts
in control solution)] x 100%.
2.7. Thioflavin T assay
The thioflavin T (ThT) assay was used to measure the inhibitory effects of the extracts
on Aβ1-42 fibrillation as previously reported by our laboratory (Yuan et al., 2015). In
each sample, the final concentrations of Aβ1-42 and test sample were adjusted to 50 µM
and 100 µg/mL, respectively. Resveratrol (RESV; at 100 µg/mL) served as the positive
control. To induce Aβ1-42 fibrillation, two individual protocols were followed. In the
thermo induced fibrillation assay, Aβ1-42 solutions at a concentration of 50 µM were
incubated at 37 °C for 72 hours with or without the herbal extracts. In the MGO-induced
fibrillation assay, 1 mM MGO was added to the reaction mixture and all samples were
incubated at 37 °C for 72 hours. Before and after incubation, 100 µL of each sample
was added to an equal volume of ThT solution (50 µM) and fluorescence was measured
on a plate reader (SpectraMax M2, Molecular Devices Corp., Sunnyvale, CA, USA) at
excitation and emission wavelengths of 450 nm and 490 nm, respectively.
2.8. Aβ1-42-AGEs assay
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In this assay, each extract was evaluated for its inhibitory effect against Aβ1-42-AGE
formation induced by methylglyoxal (MGO), a reactive carbonyl species. Briefly, 50
µM Aβ1-42 solution was mixed with 1 mM MGO to produce Aβ1-42-AGEs following
published methods (Li et al., 2013). Treatments included either 100 µg/mL of each
extract or 100 µg/mL of the positive control, AG. After 72-hour incubation at 37 °C, the
Aβ1-42-AGEs level was measured by intrinsic fluorescence using a plate reader
(SpectraMax M2, Molecular Devices Corp., Sunnyvale, CA, USA) at excitation and
emission wavelengths of 360 and 435 nm, respectively.
2.9. Acetylcholinesterase (AChE) inhibition assay
The AChE inhibitory activities of the herbal extracts were evaluated using a published
spectrophotometric method with slight modifications (Ellman et al., 1961). Brieﬂy, a
reaction mixture consisting of 100 μL of 100 mM Tris-HCl buffer (pH 8.0), 20 μL AChE
enzyme solution (0.5 U/mL) and 20 μL of test samples (concentration ranging from 25
- 300 μg/mL in 100 mM Tris-HCl buffer containing 50% methanol) was co-incubated
in the dark at 37 °C for 20 minutes in a 96-well plate. Next, 40 μL of 0.75 mM DTNB
and 20 μL of 1.5 mM ATCI were added to the reaction mixture and incubated at room
temperature for 5 min in the dark. Then the absorbance was measured at a wavelength
of 405 nm using a plate reader (SpectraMax M2, Molecular Devices Corp., Sunnyvale,
CA, USA). A 50% methanol in 100 mM Tris-HCl buffer served as the blank control
and galanthamine, a known AChE inhibitor, served as the positive control. Each sample
(at each concentration) was also tested without enzyme as background for the inherent
color present in each sample. Inhibition of AChE was calculated as: % Inhibition = [1(Asample - Abackground )/Ablank] × 100.
2.10. Cell culture conditions
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Murine microglial BV-2 cells were a kind gift from by Dr. Grace Y. Sun (University of
Missouri at Columbia, MO, USA) and human neuronal SH-SY5Y cells were obtained
from American Type Culture Collection (ATCC, VA, USA). The cells were maintained
using high glucose (4.5 g/L) DMEM/F12 supplemented with 10% heat inactivated FBS,
1% P/S (100 U/ml penicillin, 100 μg/mL streptomycin (Life Technologies,
Gaithersburg, MD, USA) and incubated in 5% CO2 at 37 °C. All test samples were
dissolved in DMSO to yield a 10 mg/mL stock solution and further diluted with media
to yield final solutions with DMSO < 0.1%.
2.11. Cell viability
Cellular viability was assessed using the Cell Titer Glo 2.0 (CTG 2.0) one step assay
(Promega). Briefly, the murine BV-2 microglial cells were seeded at 100,000 cells/mL
in a standard white walled clear bottom 96-well plate. After a 24-hour incubation
period, CTG 2.0 was added in and mixed for 2 minutes on an orbital shaker prior to
luminescence measurement on a plate reader (SpectraMax M2, Molecular Devices
Corp., Sunnyvale, CA, USA).
2.12. Quantification of nitric oxide species (NOS) by the Griess assay
The murine BV-2 microglial cells, in 24-well plates (n=4) at 85% confluency (105
cells/well, were serum-starved for 4 hours prior to the treatments. The cells were then
incubated with test samples (10 μg/mL) or the positive control, resveratrol (RESV; 5
μg/mL) for 1 hour after which inflammation was induced by lipopolysaccharide (LPS).
Cells were incubated for 23 hours and the culture media were collected and centrifuged.
The supernatants were measured for total nitric oxide species (NOS) by the Griess assay
kit (Promega, Fitchburg, WI, USA) as previously reported by our laboratory (Nahar et
al, 2014).
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2.13. In vivo Caenorhabditis elegans assay
The in vivo neuroprotective effects of the extracts were evaluated using a
Caenorhabditis elegans assay as previously reported by our group with minor
modifications (Yuan et al., 2015). Transgenic Caenorhabditis elegans (CL4176) were
obtained from the Caenorhabditis Genetics Center (University of Minnesota,
Minneapolis, MN, USA). This strain expresses a heat-induced human Ab1-42 gene in the
muscle tissues and prolonged expression of the gene leads to paralysis and death. The
stock culture was maintained at 18 °C on Nematode Growth Medium (NGM) plates
(1.7% Agar, 0.3% NaCl, 0.25% peptone, 1 mM CaCl2, 1 mM MgSO4, 5 mg/L
cholesterol, and 2.5 mM KPO4). NGM plates were seeded with 50 µL OP50 Escherichia
coli and allowed to incubate overnight at 37 °C. Before seeding of the plates, the E. coli
cultures were treated with the herbal extracts or vehicle control (0.05% DMSO). Once
the age of the worms were synchronized to reach the L3 stage, they were placed in a 25
°C incubator for 20 hours to induce the expression of the human Ab1-42 gene. After 20
hours the worms were counted every 2 hours for a total of 30 hours of incubation time.
Dead worms were characterized by lack of pharyngeal pumping or movement and >100
worms were used for each treatment. Kaplan-Meier curves and curve comparisons
statistics were generated using GraphPad Prism software.
2.14. Inhibition of cytotoxicity of murine BV-2 microglia and differentiated human
SH-SY5Y neuronal cells induced by hydrogen peroxide (H2O2)
Cellular viability was assessed using the Cell Titer Glo 2.0 (CTG 2.0) one step assay as
previously reported by our laboratory (Ma et al., 2016). Briefly, murine BV-2 microglia
and differentiated human SH-SY5Y neuronal cells were seeded at 100,000 cells/mL to
yield 80-85% confluency in a standard white walled clear bottom 96-well plate. The
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BV-2 cells were exposed to the herbal extracts and resveratrol (RESV; used as the
positive control) for 1 hour prior to exposure to 100 μM of H2O2 for 6 hours. The SHSY5Y cells were incubated with the extracts and RESV for 24 hours at 37°C prior to
exposure to 100 μM of H2O2 for 6 hours. Following incubation, CTG 2.0 was added in
a 1:1 ratio directly to existing media and mixed for 2 minutes on an orbital shaker prior
to luminescence measurement (SpectraMax M2, Molecular Devices Corp., Sunnyvale,
CA, USA).
2.15. Quantification of total tau protein levels in differentiated human SH-SY5Y
neuronal cells
The protein content collected from the cell culture media of differentiated SH-SY5Y
neuronal cells were analyzed for total tau protein levels by using an enzyme linked
immunosorbent assay (ELISA) (Thermo Fisher, Grand Island, NY, USA). The ELISA
was performed as per the manufacturer’s protocol. The SH-SY5Y cells were initially
plated on 100 mm dishes at a concentration of 100,000 cells/mL. Cells were then
differentiated for 7 days using retinoic acid (10 μM) prior to treatment with test samples
and resveratrol (RESV; used as the positive control). Once differentiated, the SH-SY5Y
cells were exposed to vehicle control (DMSO) or the herbal extracts for 24 hours. After
pre-treatment, the cells were then exposed to H2O2 (100 μM) for 6 hours, after which
the cell culture media was collected, centrifuged at 10,000 rpm for 5 minutes and
assayed for total tau protein levels.
2.16. Statistical Analysis
Unless otherwise indicated, all assays were performed in triplicate and all data were
expressed as the mean ± standard deviation (n=3). Significance was analyzed by oneway factorial ANOVA with Tukey–Kramer post hoc comparisons. A value of p<0.05
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were considered as significant. In the BSA-fructose, BSA-MGO, and ThT assays, the
inhibition rate (% inhibition) was defined using the following equation: % inhibition =
[1-(fluorescence intensity of solution with treatment/fluorescence intensity of control
solution)] x 100%.
Using a similar approach as previously reported (Seeram et al., 2008), an index score
from each individual assay was determined by assigning an index value of 100 to the
best score for each test, and then scores for the other samples were calculated using the
following formula: [(sample score/best score) × 100]. The average of the
chemical/biochemical assays for each extract was then taken for the initial
neuroprotective potential index (Table 2). Similarly, the final neuroprotective potential
index was determined by the average of the test scores from the in vitro (in BV-2 cells),
AChE inhibitory, and in vivo C. elegans assays using the aforementioned formula
(Table 4). Figure 1 shows the algorithm used to derive the overall index scores for the
medicinal plant extracts.
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3.0 Results and Discussion
3.1. Total polyphenol content and antioxidant capacities
The herbal extracts were first evaluated for their total polyphenol contents and
antioxidant activities (DPPH and FRAP assays) since several natural plant antioxidants,
for example, resveratrol (RESV; from grapes) and curcumin (from the Indian turmeric
Curcuma longa spice) have been reported to show promising neuroprotective effects
against AD (Li et al., 2012; Lim et al., 2001). As shown in Table 1, the twenty-three
medicinal plant extracts were evaluated for their phenolic content by the Folin-Ciocalteu
method based on gallic acid equivalents (GAEs). The total polyphenol contents ranged
from 1.0 to 41.2% (w/w, based GAEs) and this wide range was attributed to the diverse
types (hydrophilic vs. lipophilic) of chemical constituents found in these various
extracts. As expected, among the extracts, two well-known polyphenol-rich plants,
Punica granatum (41.2%) and Phyllanthus emblica (38.9%) showed the highest
polyphenol contents followed by Ocimum tenuiflorum (37.1%), Mucuna pruriens
(37.0%) and C. longa (31.5%). Similarly, as expected, the extracts with highest
polyphenol contents also showed the strongest antioxidant activities in both the DPPH
and FRAP assays (see Table 1). For example, the most potent antioxidant extracts in
the DPPH assay were P. emblica, P. granatum and M. pruriens, which had IC50 values
of 11.1, 13.7 and 22.4 μg/mL, respectively, followed by Cinnamomum cassia (IC50 68.9
μg/mL), O. tenuiflorum (IC50 72.5 μg/mL), Pterocarpus marsupium (IC50 73.9 μg/mL)
and Terminalia arjuna (IC50 84.3 μg/mL). All of these extracts showed superior
antioxidant activity compared to the positive control, BHT (butylated hydroxytoluene),
a synthetic commercial antioxidant (IC50 493.6 μg/mL). The antioxidant data obtained
from the FRAP assay were in agreement with the antioxidant data obtained from the
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DPPH assay. For example, at a concentration of 100 µg/mL, P. emblica showed the
highest FRAP capacity (2405.7 AAE/mg), followed by M. pruriens (2269.2 AAE/mg)
and P. granatum (2032.9 AAE/mg). Other herbal extracts which showed moderate
FRAP capacity were P. marsupium (774.9 AAE/mg), O. tenuiflorum (754.5 AAE/mg),
Mangifera indica (695.5 AAE/mg), T. arjuna (652.2 AAE/mg), and Syzygium cumini
(502.0 AAE/mg).
3.2. Anti-glycation and reactive carbonyl species (RCS) scavenging capacities
Next, the extracts were evaluated for their anti-glycative abilities and reactive carbonyl
species (RCS) scavenging activities using three individual assays. First, the BSAfructose assay was used to evaluate the inhibitory effects of the extracts on total AGEs
formation, Second, the BSA-methylglyoxal (BSA-MGO) assay was used to evaluate
the inhibitory effects of the extracts on RCS induced AGE formation, typically seen at
the middle stage of glycation (Wu and Yen, 2005). Third, the extracts were evaluated
for their direct scavenging capacity on methylglyoxal (MGO) using the MGO-trapping
assay.
As shown in Figure 2A, all twenty-three extracts (100 μg/mL) showed anti-AGEs
effects which ranged from 15.1 to 90.8% in the BSA-fructose assay. Among all of the
extracts, P. granatum showed the highest inhibition of 90.8%, which was significantly
higher than the positive control, AG (67.2%), a synthetic anti-glycative agent. Extracts
of P. emblica (85.3%) and Moringa oleifera (75.6%) also showed anti-AGE effects
superior to AG. Additionally, several other extracts showed more than 50% inhibitory
effects including O. tenuiflorum (65.3%), Foeniculum vulgare (57.4%), M. pruriens
(55.3%), P. marsupium (54.8%), Centella asiatica (51.8%) and Tinospora cordifolia
(51.0%).
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We then evaluated these herbal extracts for their inhibitory effects on MGO induced
AGEs formation. As shown in Figure 2B, P. emblica and P. granatum extracts were
the most potent inhibitors of AGE formation (i.e. 74.1% and 48.7% respectively),
superior to AG at an equivalent concentration of 100 µg/mL (44.4%). These extracts
were followed by C. longa (46.4%), P. vulgare (38.8%), C. asiatica (38.8%), P.
marsupium (37.2%), O. tenuiflorum (36.9%), T. cordifolia (35.7%), and T. arjuna
(34.7%) which were comparable to the positive control, AG (44.4%).
In addition to the anti-glycative effects of the extracts, their MGO scavenging capacity
may also contribute to their potential neuroprotective effects. Therefore, the MGO
trapping ability of the extracts were evaluated as shown in Figure 2C.

At a

concentration of 100 μg/mL, extracts of C. longa, P. granatum, and P. emblica
scavenged MGO by 99.0, 87.3, and 78.6%, respectively. This trend was similar to the
BSA-MGO assay wherein these extracts also showed the highest inhibition levels on
MGO induced glycation. The extracts of M. oleifera, O. tenuiflorum, Bacopa monnieri,
Tamarindus indica and F. vulgare also showed strong scavenging activities yielding
MGO quenching levels ranging from 55.9 to 35.0%. Notably, the positive control, AG,
a known MGO scavenging agent, showed 95.7% MGO trapping ability but at a much
higher concentration of 1000 μg/mL.
In summary, the anti-glycation activities of the most potent AGE inhibitors were P.
granatum, P. emblica, and C. longa which were attributed to their strong antioxidant
and MGO scavenging activities. The anti-AGEs effects of P. granatum is in agreement
with our previously reported study (Liu et al., 2014).
3.3. Inhibitory effects on Aβ1-42 fibrillation and Aβ1-42–AGEs formation
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Numerous studies have shown that certain forms of Aβ, such as fibrillated Aβ and
glycated Aβ (Aβ-AGEs) are more toxic than its native counterpart (Butterfield, 2002;
Koo et al., 1999; Li et al., 2013). Therefore, we evaluated the twenty-three medicinal
plant extracts for their inhibitory effects on the formation of fibrillated Aβ and glycated
Aβ, two common targets for AD treatment.
The ThT binding assay was used to evaluate the fibrillation level of human Aβ1-42. In
the thermo-induced fibrillation assay, Aβ1-42 fibril formation was confirmed by a
significant increase in ThT fluorescence after 72 hours incubation at 37 °C. The
fluorescence levels of Aβ treated with the extracts were then compared with the control
and their inhibition levels on Aβ fibrillation are shown in Figure 3A. Upon treatment
with the extracts, the lowest fibrillation level was seen in Aβ solution treated with B.
monnieri (63.3% inhibition), followed by P. granatum (61.7% inhibition), P.
marsupium (53.7% inhibition), P. emblica (47.9% inhibition) then C. longa (47.2%
inhibition). The inhibition levels of these extracts were all significantly higher than
positive control resveratrol (RESV, 31.8% inhibition), a natural phenolic compound
known for its anti-amyloidosis and neuroprotective effects (Feng et al., 2009; Li et al.,
2012).
Next, the herbal extracts were evaluated for their inhibitory abilities on MGO-induced
Aβ1-42 fibrillation using the ThT binding assay. Studies have shown that reactive
carbonyl species (RCS) such as MGO can induce Aβ fibrillation and aggregation (Chen
et al., 2007; Chen et al., 2006). Consequently, carbonyl stress conditions with elevated
RCS levels play an important role in the progression of neurodegenerative diseases
including AD. Therefore, the inhibitory effects of the extracts against MGO-induced Aβ
fibril assembly may also result in neuroprotective activities. As shown in Figure 3B,
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the highest inhibitory effect was observed in samples treated with B. monnieri (63.5%)
and C. asiatica (62.6%), with effects significantly higher than the positive control,
RESV (32.1%). In addition, extracts of P. granatum (49.9%), P. marsupium (39.1%),
Boswellia serrata (37.9%) and P. emblica (33.7%) also showed inhibitory effects
against Aβ1-42 fibrillation superior to the positive control, RESV (32.1%).
Besides fibrillated Aβ, glycated Aβ (Aβ-AGEs) produced from the modification of Aβ
by sugars and sugar metabolites also exacerbates the neurotoxicity of native Aβ (Li et
al., 2013). Therefore, we next evaluated the inhibitory effects of the herbal extracts on
the formation of glycated Aβ (Aβ-AGEs). As shown in Figure 3C, the positive control,
AG, at a concentration of 100 µg/mL, reduced glycated Aβ formation by 58.9%. Among
the extracts, T. arjuna showed the highest inhibition (83.8%) followed by P. emblica
(83.2%), and P. granatum (77.7%). Several other extracts also showed inhibition levels
superior to the positive control, AG, including T. indica (77.1%), S. cumini (76.2%),
and Salacia reticulata (75.5%) extracts.
Based on the data obtained from these six bioassays, namely, total polyphenol content,
anti-oxidant capacity (DPPH and FRAP assays), anti-glycation effects, MGO trapping
activity, Aβ fibrillation inhibition, and Aβ-AGEs inhibition, index scores were
generated for each extract as previously reported (Seeram et al., 2008) and these results
are summarized in Table 2. Extracts of P. granatum and P. emblica showed the highest
score (91 and 90, respectively), followed by M. pruriens (70), C. longa (59) and C.
asiatica (57). The medicinal plant extracts with a neuroprotective potential index score
≥ 40, namely, the top twelve candidates, were selected for further evaluations for their
neuroprotective potential using in vitro (BV-2 cells), AChE inhibitory, and in vivo
(Caenorhabditis elegans) bioassays.
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3.4. Inhibition of acetylcholinesterase (AChE) enzyme activity
Inhibitors of the acetylcholinesterase (AChE) enzyme are currently used as treatments
for mild to moderate AD in human subjects (Birks et al., 2000) and this assay is widely
used to screen for candidates with anti-AD potential (Birks, 2006). Therefore, the
medicinal plant extracts (see Table 2) which had a neuroprotective potential index score
≥ 40 (from the initial set of bioassays described in Sec. 3.1 -3.3) were next evaluated for
their inhibitory effects on the AChE enzyme. As shown in Table 3, the top four
candidates namely, M. pruriens, P. emblica, P. granatum, and C. longa showed AChE
inhibitory effects of 48.1, 43.1, 35.1, and 11.3% at 100 μg/mL, respectively, with IC50
values ranging from 91.3 to 304.6 μg/mL. In addition, among the twelve herbal extracts,
T. arjuna also showed inhibitory effects against the AChE enzyme with an IC50 value
of 313.6 μg/mL (Table 3).
3.5. Inhibition of lipopolysaccharide (LPS)-induced nitric oxide species (NOS)
production in murine BV-2 microglial cells
The medicinal plant extracts (see Table 2) which had a neuroprotective potential index
score ≥ 40 (from the initial set of bioassays described in Sec. 3.1 -3.3) were next
evaluated for their effects on LPS-induced neuroinflammation in an established in vitro
murine BV-2 microglia cell model. As shown in Figure 4, seven of these extracts
inhibited NOS levels at 10 μg/mL. The most active extracts were P. marsupium and C.
cassia, which reduced NOS production by 23.6 and 22.2%, respectively. Also, C.
asiatica, C. longa, P. emblica, P. granatum, and B. monnieri suppressed NOS
production by 20.8, 19.4, 19.0, 16.7 and 15.0%, respectively. The extracts of M.
pruriens, O. tenuiflorum, and M. oleifera did not significantly reduce NOS production
while T. arjuna and S. reticulata extracts increased the levels of NOS. The positive

51

control, RESV (10 μg/mL), showed a 38.6% reduction of NOS production in the LPSstimulated BV2 cells.
3.6. Reduction on Aβ1-42 induced neurotoxicity and paralysis in Caenorhabditis
elegans
Next, the twelve extracts (which had a neuroprotective potential index score ≥ 40 as
described above) were evaluated using an in vivo model using a transgenic C. elegans
strain (CL4176) as previously reported by our group (Yuan et al., 2015). The CL4176
strain has a mutation of human Aβ1-42 expression in the muscle of the worms and the
deposition of Aβ1-42 leads to neurotoxicity and paralysis. As shown in Figure 5, the heat
shock induced Aβ1-42 neurotoxicity decreased the survival rate of C. elegans to 15.3%
at 30 hours. However, among the extracts, P. emblica, P. granatum, M. pruriens, and
C. longa significantly increased the survival rate of C. elegans to 47.8, 45.8, 44.1, and
39.1%, respectively. Several of the other extracts including P. marsupium, C. cassia, M.
oleifera, B. monnieri, and O. tenuiflorum increased the survival rate of C. elegans from
33.3 to 16.7% while S. reticulata and T. arjuna did not show any neuroprotective effects
with a survival rate of C. elegans of 6.7 and 4.8%, respectively. Based on the results
from the C. elegans lifespan assay, P. emblica, P. granatum, M. pruriens, and C. longa
were ranked among the top extracts which is in agreement with the ranking obtained
from the in vitro BV-2 cell assay, wherein C. longa, P. emblica, P. granatum, and M.
pruriens were also the most active extracts.
3.7. Evaluation of herbal extracts against H2O2 induced cytotoxicity in murine BV2
microglia and human neuronal SH-SY5Y cells
It is well established that oxidative stress is linked with the pathology of several
neurodegenerative diseases including AD (Butterfield, 2002; Christen, 2000).
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Therefore, based on the bioassays described in Sec. 3.4 -3.6, a final neuroprotective
potential index score was calculated (see Table 4) and the extracts which had an index
score ≥ 60, namely, P. granatum, P. emblica, M. pruriens and C. longa, were selected
for further evaluation of their neuroprotective effects against H2O2 induced cytotoxicity
in murine BV-2 microglia and differentiated human SH-SY5Y neuronal cells. As
shown in Figure 6A, the cell viability of the H2O2-treated murine microglial BV-2 cells
decreased by 31.7% as compared to the control group. When the H2O2-exposed cells
were subsequently treated with the herbal extracts (concentration of 10 µg/mL), M.
pruriens, P. emblica, P. granatum, and C. longa increased cell viability by 30.2, 22.3,
12.3, and 5.6%, respectively, as compared to the cells exposed to H2O2 alone. Similarly,
as shown in Figure 6B, the cellular viability of H2O2-treated human neuronal SH-SY5Y
cells decreased by 48.2% as compared to the control group. When the H2O2-exposed
cells were subsequently treated with the herbal extracts (each at a concentration of 10
µg/mL), C. longa, M. pruriens, and P. emblica significantly increased the cell viability
by 109.1, 90.6, and 76.9%, respectively. Resveratrol (RESV), which served as the
positive control, also increased cell viability of H2O2-treated murine BV-2 microglia
(19.5%) and differentiated human SH-SY5Y neuronal (79.3%) cells (Figure 6).
3.8. Evaluation of herbal extracts on tau protein production in differentiated
human SH-SY5Y neuronal cells
Studies have shown that in neurodegenerative models, including AD, neurons
undergoing cell stress release tau proteins which on hyperphosphorylation form
neurofibrillary tangles which can ultimately lead to cell death (Gomez-Ramos et al.,
2006). Therefore, as described above (see Section 3.7), the extracts which had an index
score ≥ 60, namely, P. granatum, P. emblica, M. pruriens and C. longa, were selected
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for further evaluation of their inhibitory effects on tau protein production in human
neuronal SH-SY5Y cells. As shown in Figure 6C, extracts of C. longa, P. granatum,
M. pruriens, and P. emblica reduced extracellular tau protein levels by 83.7, 82.6, 66.4,
and 52.4%, respectively.
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4.0 Conclusions
In summary, using bioassays with established links between AD and oxidative stress,
carbonyl stress, glycation, Aβ fibrillation, Aβ-AGE formation, AChE inhibition, and
neuroinflammation, an AD Neuroprotective Potential Algorithm (NPA) was developed
as part of a strategy to help guide the selection and evaluation of medicinal plant
candidates for future AD based research. From the current study, four extracts identified
with a cumulative neuroprotective potential index score ≥ 60 were Phyllanthus emblica
(amla; Indian gooseberry), Mucuna pruriens (velvet bean), Punica granatum
(pomegranate) and Curcuma longa (curcumin; turmeric). Interestingly, published
animal data support the neuroprotective effects of two of these extracts namely, P.
granatum (Yuan et al., 2015; Ahmed et al., 2014) and C. longa (Ringman et al., 2005)
against AD. While the other two extracts remain underexplored for their anti-AD
potential, P. emblica has been shown to improve memory deficits in mice (Ashwlayan
and Singh, 2011) and M. pruriens has been shown to have protective effects against
Parkinson’s disease in human subjects (Katzenschlager et al., 2004).
There are several limitations to the NPA developed herein, primarily, due to the fact
that botanical extracts are complicated mixtures containing multiple ‘multi-targeting’
phytochemicals which undergo complex metabolic processes in vivo (including
metabolism by the liver enzymes and gut microflora) which influence their
bioavailability, metabolism, excretion, and generation of ‘further’ bioactive metabolites
(Wang et al., 2015; Yuan et al., 2015; Wang et al., 2014). For example, our group has
recently reported that the gut microbial metabolites produced from the colonic
microflora metabolism of the natural ellagitannins present in the pomegranate (P.
granatum) fruit are potentially brain absorbable and may contribute to the anti-AD
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effects reported for this natural product (Yuan et al., 2015). Therefore, a major limitation
of the NPA developed here is the lack of critical in vivo data (accumulated from animal
models) which would account for the aforementioned important physiological
considerations (Singh et al., 2008; Ebrahimi and Hermann, 2012). Other limitations of
the NPA include utilizing additional AD-targeted bioassays and its validation with an
increased sample size of medicinal plant extracts and their combinations thereof.
Nevertheless, given all of these limitations, the NPA may be utilized in consideration
with published literature data (when available) of animal and human studies, traditional
and ethnomedicinal use, etc., as part of a more comprehensive research strategy to guide
the selection of promising medicinal plant candidates for future AD based research
using in vivo models.
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STEP 1: Measure antioxidant capacity (Table 1)
- Total polyphenol content (Folin-Ciocalteu assay)
- Free radical scavenging (DPPH assay)
- Ferric reducing antioxidant power (FRAP assay)
STEP 2: Measure inhibitory effects on glycation (Figure 2)
- Fructose-induced AGEs formation
- Carbonyl species (MGO)-induced AGEs formation
- MGO trapping ability
STEP 3: Measure inhibitory effects on Aβ fibrillation (Figure 3)
- Thermo-induced Aβ fibrillation
- Carbonyl species (MGO)-induced Aβ fibrillation
- Aβ-AGEs formation
Ø Obtain initial neuroprotective potential index (Table 2)
Ø Select candidates with score ≥ 40 (modifiable)
STEP 4: Measure inhibitory effects on AChE activity (Table 3)
STEP 5: Measure in vitro inhibitory effects on neuroinflammation
(Figure 4)
- Nitric oxide species (NOS) production in murine BV-2 microglia cells
STEP 6: Measure in vivo neuroprotective effects (Figure 5)
- Aβ induced paralysis in Caenorhabditis elegans
Ø Obtain final neuroprotective potential index (Table 4)
Ø Select candidates with score ≥ 60 (modifiable)
Figure 1. Neuroprotective Potential Algorithm (NPA) for selecting and evaluating
medicinal plants as potential candidates for Alzheimer’s disease based research.
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Figure 2. Inhibitory effects of medicinal plant extracts (100 µg/mL) on D-fructose
induced BSA AGEs formation (A), MGO induced BSA AGEs formation (B) and MGO
scavenging capacity (C). Aminoguanidine at 100 µg/mL served as the positive control.
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Figure 3. Inhibitory effects of medicinal plant extracts (100 µg/mL) on thermo-induced
Aβ fibrillation (A), MGO induced Aβ fibrillation (B) and MGO induced Aβ-AGEs
formation (C). Resveratrol at 100 µg/mL served as the positive control for Aβ
fibrillation studies (A and B) while aminoguanidine at 100 µg/mL served as the positive
control for Aβ-AGEs study (C).
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Figure 4. Anti-neuro-inflammatory effects of medicinal plant extracts on murine BV-2
cells microglial cells by measuring NOS production induced by LPS. BV-2 cells were
treated with each extracts (10 μg/mL) for 1 h followed by exposure to LPS (1 μg/mL)
for 24 h. The cell culture media were used to assay the amount of NOS production by
the Griess assay. Data are presented as means ± SDs of three independent experiments.
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Figure 5. Protective effects of medicinal plant extracts against neurotoxicity and
paralysis in Caenorhabditis elegans in vivo. Mobility curves of transgenic (CL4176)
C. elegans 30 hours post Aβ1-42 induction of muscular paralysis at 25 °C. Kaplan-Meier
mobility plots of C. elegans worms fed on twelve extracts [Control (NGM), in dot line;
(A-L) test samples: (NGM + 10 μg/mL test sample), in solid line]
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Figure 6. Protective effects of medicinal plant extracts (10 µg/mL) on H2O2 induced
cytotoxicity in murine BV-2 microglia (A) and differentiated human SH-SY5Y
neuronal cells (B). Cellular viability was assessed using Cell Titer Glo 2.0 (CTG 2.0)
one step assay. C: Inhibitory effects of medicinal plant extracts (10 µg/mL) on tau
protein levels in differentiated SH-SY5Y neurons (C). All data are presented as mean
± SDs of three independent experiments.
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Table 1. Medicinal plants and their total polyphenol contents and antioxidant activity
(DPPH and FRAP assays)
Species

Common name

Traditional use

Plant part

Total
polyphen
ol
content%a

Azadirachta indica

Neem

antidiabetic

Leaves

Bacopa monnieri

Waterhyssop

enhance memory

Boswellia serrata
Elettaria
cardamomum

Indian olibanum
Cardamom

joint health
digestive disord
ers

Centella asiatica

Gotu kola

Cinnamomum cassia

DPPH
activityb

FRAP
activit
yc

12.9 ± 0.4

781.3 ±
49.0

203.8
± 9.7

Whole
herb

3.4 ± 1.9

n.a.

105.6
± 5.8

Gum resin

2.4 ± 0.1

n.a.

11.8 ±
1.8

Fruit

2.9 ± 0.7

n.a.

n.a.

antidiabetic

Whole
herb

27.0 ± 1.6

263.1 ±
25.4

224.2
± 10.9

Cinnamon

antidiabetic

Bark

22.4 ± 1.0

68.0 ± 10.3

324.2
± 21.1

Curcuma longa

Turmeric, Curcumin

antiinflammatory

Rhizomes

31.5 ± 1.8

111.4 ±
25.2

407.6
± 12.8

Foeniculum vulgare

Fennel

antiinflammatory

Seeds

24.0 ± 1.9

544.0 ±
14.6

179.3
± 6.2

Gymnema sylvestre

Gymnema

antidiabetic

Leaves

21.0 ± 1.2

468.0 ± 9.4

253.4
± 8.0

Mangifera indica

Mango

clearing
digestion

Leaves

27.9 ± 2.8

60.6 ± 5.7

695.5
± 21.7

Moringa oleifera

Moringa

joint health

Fruit

19.9 ± 2.5

758.9 ±
23.8

123.6
± 7.1

Mucuna pruriens

Velvet bean

neurodegenerati
ve

Seeds

37.0 ± 2.4

22.4 ± 1.8

2269.2
± 61.3

Ocimum tenuiflorum

Holy basil

spice

Leaves

37.1 ± 1.7

72.5 ± 4.2

754.5
± 16.8

Phyllanthus emblica

Amla

antiinflammatory

Juice

38.9 ± 2.3

11.1 ± 1.7

2405.7
± 5.9

Pterocarpus
marsupium

Indian Kino

antidiabetic

Bark

20.6 ± 1.4

73.9 ± 11.0

774.9
± 17.3

Punica granatum

Pomegranate

antidiabetic

Fruit Peel

41.2 ± 0.7

13.7 ± 0.7

2032.9
±57.5

Salacia reticulata

Salacia

antidiabetic

Roots

22.9 ± 1.4

791.5 ± 6.1

400.9
± 13.3

Sesamum indicum

Sesame

spice

Seeds

1.0 ± 0.1

n.a.

64.9
±0.5

Syzygium cumini

Jamun, Black plum

antidiabetic

Fruit pulp

21.3 ± 3.2

129.9 ± 2.7

502.0
± 4.5

Tamarindus indica

Indian date

fever

Fruit

3.6 ± 1.6

614.8 ±
12.7

75.2 ±
2.7

Terminalia arjuna

Arjuna

heart disease

Bark

24.6 ± 0.9

84.3 ± 19.2

652.2
± 19.9

Tinospora cordifolia

Guduchi

anticancer

Stem

8.8 ± 0.5

571.1 ±
212.9

241.6
± 2.7
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Withania somnifera

Ashwagandha,
ginseng

BHT*

─

Indian
anti-ulcer

Roots

─

─

a

25.7 ± 0.4

279.6 ±
20.1

166.1
± 3.1

─

493.6 ± 8.7

─

(w/w % as of gallic acid equivalents); bvalue = IC50 (μg/mL), n.a. = not active (IC50
>2000 μg/mL); cn.d. = not detected; cvalue = ascorbic acid equivalents/mg dry plant
material, n.a. = not active; *Positive control: Butylated hydroxytoluene, BHT
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Table 2. Initial screening for neuroprotective potential index based on total polyphenol
content, antioxidant, anti-glycation, and anti-Aβ fibrillation activities

AntiAGEsb

Anti
AβAGEs

AntiAβ
Agg.c

AntiAβ
Agg.d

Neuroprotective
potential
index

100

66

93

79

97

91

90

94

100

99

53

76

90

94

85

61

39

63

43

63

70

52

17

99

41

63

71

37

75

59

66

67

9

23

57

52

74

99

63

57

P. marsupium

50

59

32

3

60

50

76

62

83

53

55

87

13

12

43

42

56

45

57

46

90

63

31

45

72

50

50

0

1

45

9

C. cassia
O.
tenuiflorum
T. arjuna

60

56

27

22

47

47

100

25

8

44

10

B. monnieri

8

3

4

45

35

37

49

100

100

42

11

M. oleifera

49

32

5

64

83

40

7

49

43

41

12

S. reticulata

56

22

17

11

42

30

90

41

64

41

13

S. cumini

52

53

21

0

21

18

91

30

26

35

14

F. vulgare

59

35

7

40

63

52

40

0

0

33

15

T. indica

9

41

3

43

48

42

92

11

0

32

16

W. somnifera

63

36

7

10

38

41

81

7

0

31

17

T. cordifolia

21

38

10

16

56

48

89

0

0

31

18

M. indica

68

68

29

11

42

44

0

19

0

31

19

G. sylvestre

51

43

11

13

26

23

38

28

8

27

20

A. indica

31

21

8

0

26

23

79

13

32

26

21

S. indicum

2

1

3

25

47

40

46

30

17

23

22

B. serrata
E.cardamomu
m

6

7

0

14

19

18

34

60

46

23

7

2

0

12

48

34

40

0

0

16

Ranki
ng

Plant
species

Total
phenolic
content

DPPH

FRAP

MGO
trapping

AntiAGEsa

1

P. granatum

100

99

85

100

2

P. emblica

95

100

100

3

M. pruriens

90

95

4

C. longa

77

5

C. asiatica

6
7
8

23
a

BSA AGEs formation induced by D-fructose; bBSA AGEs formation induced by
methylglyoxal (MGO); cthermo induced Aβ fibrillation (37 °C); dMethylglyoxal (MGO)
induced Aβ fibrillation
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Table 3. Inhibitory effects on AChE activity of selected medicinal herbal extracts (top
12 based on initial screening)
AChE inhibition (%) at 100
μg/mL

AChE IC50
(μg/mL)

P. granatum

35.06 ± 2.93

304.62 ± 1.27

P. emblica

43.11 ± 1.72

163.92 ± 3.55

M. pruriens

48.11 ± 2.78

91.35 ± 2.80

C. longa

11.31 ± 1.81

─b

C. asiatica

n.a. a

─

P. marsupium

n.a.

─

C. cassia

n.a.

─

B. monnieri

n.a.

─

O. tenuiflorum

n.a.

─

M. oleifera

n.a.

─

T. arjuna

12.88 ± 2.58

313.58 ± 6.21

S. reticulata

7.64 ± 1.43

─

galanthamine c

68.50 ± 1.10

5.37 ± 3.79

Plant Species

a

n.a. = not active; shown as mean values ± SD (n ≥ 3). b ─, > 600 μg/mL. c Used as
positive control at 12 μg/mL.
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Table 4. Final screening for medicinal plant extracts for neuroprotective potential index
based on the AChE inhibitory activity assay, in vitro anti-neuro-inflammatory effects in
murine BV-2 microglial cells, and in vivo neuroprotective effects against Aβ1-42 induced
neurotoxicity and paralysis in C. elegans
AChE
inhibitory
activity
assay

Neuroinflammation
assay

in vivo C.
elegans assay

Neuroprotective
potential index

Ranking

Plant species

1

P. emblica

90

80

100

90

2

M. pruriens

100

49

96

82

3

P. granatum

73

71

96

80

4

C. longa

23

82

82

62

5

P. marsupium

0

100

60

53

6

C. asiatica

0

88

70

53

7

C. cassia

0

94

42

45

8

B. monnieri

0

64

38

34

9

O. tenuiflorum

0

27

35

21

10

M. oleifera

0

19

42

20

11

S. reticulata

8

0

14

7

12

T. arjuna

12

0

10

7
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MANUSCRIPT 3
Manuscript 3 appears as published in Natural Product Communications.
Phenolic compounds isolated and identified from Amla (Phyllanthus emblica) juice
powder and their antioxidant and neuroprotective activities. Rose, Kenneth N.; Wan,
Chunpeng; Thomas, A; Seeram, Navindra P.; Ma, Hang. (2018). Natural Product
Communications. 13, 1309-1311.
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Abstract
The edible fruit of Phyllanthus emblica (known as amla and Indian gooseberry) is
widely used in Eastern traditional medicinal systems for a variety of ailments. Our
group has previously reported that an amla juice powder shows neuroprotective
effects in several in vitro and in vivo assay models but its chemical constituents and
their neuroprotective activity remain unknown. Therefore, we conducted a
phytochemical investigation of amla juice powder and evaluated the antioxidant and
neuroprotective effects of the isolates. Ten phenolics (1-10), including gallic acid (1),
five gallic acid derivatives (2-6), ellagic acid (7), and three ellagic acid derivatives
(8-10), were isolated and identified with compounds 8-10 being reported from amla
for the first time. All of the isolates showed antioxidant effects in the DPPH assay
with IC50 values ranging from 6-158.9 µM superior to the synthetic commercial
antioxidant, butylated hydroxytoluene (IC50 = 371.4 µM). In addition, compound 8
reduced β-amyloid-induced neurotoxicity in a transgenic Caenorhabditis elegans
model by increasing their survival rate by 28.3% compared to the control group. This
study adds to the growing body of evidence supporting the potential health benefits
of amla and supports the functional food and nutraceutical applications of amla juice
powder.
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1.0 Introduction
Amla (Phyllanthus emblica), also known as Indian gooseberry, is a deciduous tree that
commonly grows in the subtropical and tropical regions of Southeast Asia including
southern India and China. Various parts of the amla plant, especially its fruit, are
traditionally used as folk remedies for numerous ailments in traditional Chinese and
Indian (Ayurvedic) medicinal systems [1, 2]. Previous phytochemical studies reported
that the major bioactive compounds present in amla fruits are phenolics including
hydrolyzable tannins (both ellagitannins and gallotannins), anthocyanins, flavonoids,
flavonols, and phenolic acids [2-6]. While amla fruits are regionally consumed as a
food and spice, because of seasonal factors and perishability, the fruits are only
available for a short period. Therefore, an amla juice powder is a viable option to
preserve the fruit’s bioactive constituents for nutraceutical and functional beverage
applications. Our laboratory has reported on the development of a neuroprotective
potential algorithm (NPA) to screen medicinal plant extracts in which an amla juice
powder ranked top among twenty Ayurvedic medicinal plants [7]. However, whether
the bioactive compounds present in this particular amla juice powder are similar or
different from amla fruits remain unknown.
In our continued efforts to further investigate the biological activities of the top
ranking medicinal plants using the NPA [7], herein, we sought to isolate and identify
the bioactive compounds from the aforementioned amla juice powder and evaluate
their antioxidant and neuroprotective effects using assays adopted from the NPA. In
the current study, ten phenolic compounds (1-10) were isolated from the amla juice
powder and their chemical structures (shown in Figure 1) were identified by
comparing their NMR and mass spectroscopic data with published data (see
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References 8-14). Ten isolates were identified as gallic acid(1) [8], methyl gallate (2)
[9], 1-O-galloyl-glucoside (3) [10], mucic acid 3-O-gallate (4) [11], corilagin (5) [12],
1,6-di-O-galloyl- glucoside (6) [10], ellagic acid (7) [8], ellagic acid-4-O-glucoside
(8) [8], ellagic acid-4-O-xyloside (9) [13], and ellagic acid-4-O- rhamnoside (10) [14].
While compounds 1-7 have been previously reported from amla fruit [2-6], to the best
of our knowledge, compounds 8-10 are being reported from this plant for the first time.
The amla juice powder and its isolates were evaluated for antioxidant and anti-βamyloid effects in Caenhorhabditis elegans. Amla juice powder had an IC50 value of
28.9 µg/mL in the antioxidant (DPPH) assay and compounds 1-10 showed superior
antioxidant activities (IC50 values = 6.0, 3.1, 2.7, 1.6, 4.9, 3.0, 2.6, 73.4, 26.3, and
158.9 µM, respectively) compared to the positive control, butylated hydroxytoluene
(a synthetic commercial antioxidant; IC50 = 371.4 µM). The neuroprotective effects
of the amla juice powder and compounds 1-10 were evaluated using a transgenic C.
elegans nematode model (CL1476). Amla juice powder (at 10 µg/mL) significantly
reduced the β-amyloid-induced neurotoxicity in the nematodes and increased their
survival rate by 28.2% as compared to the control group (Figure 2A). Compound 8
(at 10 µM) increased the survival rate of nematodes by 28.3% as compared to the
control group (Figure 2B).
None of the other isolates showed significant activity in this assay. However, further
studies would be required to evaluate the neuroprotective effects of this amla juice
powder and its isolated compounds. In summary, ten phenolic compounds were
isolated and identified from an amla juice powder and their antioxidant and
neuroprotective effects were evaluated. This study adds to the growing body of
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evidence supporting the potential health benefits of amla and supports the functional
food and nutraceutical applications of the fruit juice powder.
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2.0 Experimental
2.1 General
The 1H and

13

C nuclear magnetic resonance spectroscopic experiments were

conducted in methanol (CD3OD) on a Varian 500 MHz instrument. HR-ESIMS data
were acquired on Waters SYNAPT G2-S QTOFMS system. Solvents were either ACS
or HPLC grade purchased from Wilkem Scientiﬁc (Pawtucket, RI, USA). High
performance liquid chromatography (HPLC) was performed on a Hitachi Elite
LaChrom system (Pleasanton, CA, USA) consisting of a L-2130 pump, L-2200
autosampler, and a L-2455 diode array detector.
2.2 Plant material
Amla juice powder was kindly provided by Verdure Sciences (Noblesville, IN, USA)
and voucher specimens (LEO2JP110210) are deposited in the Heber Youngken
Herbarium and Greenhouse at the College of Pharmacy, the University of Rhode
Island, RI, USA.
2.3 Extraction and isolation
Amla juice powder (20 g) was dissolved in 50 mL DI water and chromatographed on
a XAD-16 resin column (3 × 10 inch) eluted with a gradient system of MeOH/H2O
(0/100, 50/50 and 100/0; v/v) to afford three sub-fractions (A1-A3). Sub-fraction A2
was separated by medium-pressure liquid chromatographic (MPLC) column (2 × 15
cm) with C18 resin eluted with a gradient system of MeOH/H2O (10/90 to 40/60; v/v)
to afford four sub-fractions (B1-B4). Sub-fraction B1 was separated by semipreparative HPLC eluted with MeOH/H2O (11/89; v/v) to yield compounds 1 (229
mg, tR = 13.0 min), 3 (18.6 mg, tR = 8.0 min), and 4 (12.6 mg, tR = 12.0 min). Subfraction B2 was separated by semi-preparative HPLC eluted with a gradient system
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of MeOH/H2O (18/82 to 35/65; v/v) to yield compounds 2 (16.0 mg, tR = 15.16 min),
and 6 (8.6 mg, tR = 12.58 min). Sub-fraction B3 was separated by semi-preparative
HPLC eluted with a gradient system of MeOH/H2O (18/82 to 40/60; v/v) to yield
compound 5 (13.1 mg, tR = 14.24 min). Fraction A3 was separated on the C18 MPLC
column (2 × 15 cm) eluted with a gradient system of MeOH/H2O (3:7 to 8:2, v/v) to
afford 4 sub-fractions (C1-C4). Sub-fractions C4 was separated by a Sephadex LH-20
resin column (2 × 58 cm) eluted with MeOH to afford 3 sub-fractions (D1-D3). Subfractions D2 was separated by semi-preparative HPLC eluted with a gradient system
of MeOH/H2O (45/55 to 68/32; v/v) to yield compounds 7 (62.9 mg, tR = 17.8 min),
8 (4.5 mg, tR = 11.6 min), 9 (3.9 mg, tR =
15.3 min) and 10 (4.1 mg, tR = 16.3 min).
2.4 Antioxidant activity
The antioxidant activity was evaluated using the 2,2-diphenyl-1-picrylhydrazyl
(DPPH) assay [15, 16]. Briefly, 100 µL of test sample (1-1000 µg/mL for amla juice
powder and 1- 500 µM for the isolates) was mixed with 100 µL of DPPH dissolved
in methanol (0.25 mM) in a 96-well plate. The plate was incubated at room
temperature in the dark for 35 min and then the absorbance of each well was read at
517 nm using a plate reader (SpectraMax M2, Molecular Devices Corp., Sunnyvale,
CA, USA).
2.5 In vivo anti-neurotoxicity assay (Caenorhabditis elegans assay)
C. elegans (CL1476) were obtained from the University of Minnesota
Caenorhabditis Genetics Center. Worms were grown on nematode growth agar in
Petri dishes maintained at 16 C. UV-killed OP50 E. coli was plated as a food source
before the worms were introduced. Worms were age synchronized via the standard
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hypochlorite method [7, 17]. Age synchronous C. elegans were washed from the Petri
dish with liquid nematode growth medium. Aliquots of the washed worms were
placed into the wells of a 96-well plate. A microscope was used to ensure that
approximately 20 worms were placed into each well with a final volume of 100 µL
diluting with liquid nematode growth medium. Amla juice powder (10 µg/mL) or
each of the phenolic compounds (10 µM) was added to each well and DMSO (0.01%)
served as vehicle control. Worms were placed at 16°C for 24 hours after treatment
and then a baseline count of living worms was taken followed by incubation at 25°C
for the duration of the experiment. Worms were counted every hour for 6 hours and
considered dead if they were not moving or pumping their pharynx. Kaplan-Meier
survival curves were created using GraphPad Prism 7 software.
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Figure 1: Chemical structures of compounds 1-10 from amla juice powder
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Figure 2: Protective effects of amla juice powder (10 µg/mL; A) and compound 8 (10
µM; B) against neurotoxicity and paralysis in C. elegans in vivo. Kaplan-Meier
mobility plots of C. elegans worms treated with test sample [Control (NGM), in dotted
line; test samples: (NGM + amla juice powder or compound 8), in solid line].
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CHAPTER 2
MOLECULAR BIOLOGY AND MASS SPECTROMETRY TECNIQUES FOR THE
DECONCOLUTION OF POTENTIAL MECHANISMS OF ACTIONS OF
ISOLATED PURE COMPOUNDS FROM TERRESTRIAL PLANT SOURCES
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ABSTRACT
Recently, there has been increasing interest in gut microflora’s effects on human
health. Gut microflora may contribute to human health by the biotransformation of
compounds found in food to metabolites that may differ significantly in terms of
structure and bioactivity from their parent compounds. These compounds may be
beneficial to health and particularly to brain health. Gut microbiota metabolites are
often smaller and less polar than their parent molecules, increasing the likelihood of
passive transport across the blood-brain barrier. Urolithins are a class of compounds
that result from the biotransformation of ellagitannins by gut the microbiota.
Ellagitannins are common in several edible botanical sources such as walnuts,
pomegranates, and oak-aged beverages. Urolithins have been studied regarding cancer
cell viability, however, recent research has suggested that urolithins have a
neuroprotective effect as they perform well in screening assays against amyloid-binduced toxicity. Therefore, we hypothesized that a mechanism of action must exist to
explain their neuroprotective effects. Using proteomics to evaluate the effects of
urolithin treatment on protein expression and a technique known as drug affinity
responsive target stability (DARTS) to assess protein targets of urolithins, we were
able to demonstrate that the model compound, methylated Urolithin B, can increase
the activity of complex I in a human neuroblastoma cell model and can inhibit the
activity of the DNA repair protein poly ADP-ribose polymerase-1 at nanomolar
concentrations. These mechanisms can help to explain the antiproliferative effects of
urolithins, through PARP-1 inhibition, and possibly the neuroprotective effects
through increases in complex I activity.
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1.0 Introduction
Complex I is a group of proteins that serves a vital role in the electron transport chain
as it develops the electron gradient across the mitochondrial membrane necessary for
the production of ATP.1 Of the five complexes within the mitochondria, complex I
initiates the electron transport chain. Decreases in complex I activity affect the other
constituents of the electron transport chain and therefore alters the respiration capacity
of the mitochondria2. Deficiencies in complex I function have been linked to several
disorders including mitochondrial diseases, neurological disorders, and inflammatory
diseases.3,4 Therefore, restoring complex I activity to basal levels may have a
therapeutic benefit.

Urolithins are gut microbiota metabolites of ellagitannins which are found in several
food sources such as walnuts, pomegranates, and oak-aged beverages.5 Urolithins have
been studied heavily regarding their anti-cancer effects, particularly in colon cancer
where urolithin concentrations are presumably at their highest concentration within the
body.6 Several groups have identified mechanisms of action for urolithins’ anti-cancer
effect including p21 upregulation and inhibition of EphA2 phosphorylation.7,8

Recently, urolithins have been identified to have beneficial effects in inflammatory,
neurodegenerative, and mitochondrial disease models.9,10 The mechanisms responsible
for urolithins’ anti-cancer effects are unlikely to be responsible for the observed
effects in other diseases models. Therefore, urolithins may be acting upon separate
pathways not related to their anti-cancer activity that explains their efficacy in a
variety of disease models. Recent research has demonstrated that urolithin A increases

91

mitochondria respiration capacity.9 With this knowledge, we focused our investigation
for urolithins’ mechanism of action to the mitochondria. Herein, we demonstrate
through several in vivo, in vitro, and advanced proteomic methods that methylated
urolithin B (mUB), a model compound, improves oxidative stress resistance in C.
elegans, upregulates a core component of complex I, and restores complex I activity to
normal levels in a high oxidative stress environment. Furthermore, we assert that mUB
induced increases in complex I activity is responsible, in part, for urolithins’ efficacy
in non-oncology disease models.

To model a broad range of diseases where oxidative stress plays a role in disease
progression, we use Caenorhabditis elegans treated with the pro-oxidant 5-hydroxy1,4-naphthalenedione (juglone).11 Treatment with juglone leads to the production of
reactive oxygen species and significantly reduces the lifespan of C. elegans. When
juglone is co-administered with mUB, C. elegans lifespan is significantly increased
(Figure 1). Even at mUB concentrations as low as 1µM, the lifespan of C. elegans was
increased by approximately 20% with maximum life extension at 5µM increasing
lifespan by 33%. Given that this model relies on the production of ROS to be
detrimental to C. elegans lifespan, it is likely that compounds that can scavenge free
radicals would be efficacious. However, urolithins can act as both pro- and
antioxidants depending on the cellular context.12 Therefore, the extension of lifespan
in C. elegans may be due to mechanisms unrelated to urolithins’ antioxidant
properties.
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To determine which mechanisms are responsible for the extension of lifespan in
juglone treated C. elegans we used LC-MS/MSall with SWATH acquisition. This data
independent acquisition method is on the cutting edge of proteomics research and
holds several advantages over traditional LC-MS based proteomic approaches
including reproducibility and enhanced quantification.13 Using SWATH acquisition
were identified 9 of the 12 C. elegans mitochondrial proteins from the UniProt
database and created a heat map of their relative intensities (Figure 2). The protein
NADH-ubiquinone oxidoreductase core chain 4L (NU4LM) was expressed nearly 2fold higher in C. elegans treated with mUB. NU4LM is a part of the minimal
components necessary to the function of complex I which creates the electron gradient
across the mitochondrial membrane. Mutations of complex I are correlated with the
hereditary mitochondrial disease Leber’s optic neuropathy and mitochondrial
encephalopathy.14,15

Being a core component of complex I, we hypothesized that overexpression of
NU4LM would increase the activity of complex I. To study the relationship between
complex I and mUB we used human neuroblastomas, SH-SY5Y, as readily available
kits exist for complex I activity in humans and other mammals, but not for C. elegans.
When cells are treated with hydrogen peroxide, complex I activity is reduced to
approximately half of its basal level. Co-administering hydrogen peroxide and mUB at
all tested concentrations (1, 5, and 10 µM) returns complex I activity to near basal
level (Figure 3).
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Our findings are in agreement with recently published research describing urolithin
A’s ability to improve cellular respiration9. Increases in complex I function provide an
explanation for this activity as short-term administration of urolithin A’s does not
increase the number of mitochondria within a cell, but energy output increased.
Furthermore, several of the diseases in which urolithins have been identified as being
beneficial for such as inflammatory and neurodegenerative are possibly due, in part, to
ROS accumulation16. As demonstrated in figure 3, excessive ROS leads to decreases
in complex I activity and mUB restores complex I activity to near basal levels.
Reduction in complex I activity leads to the degradation of mitochondrial membrane
potential which initiates the cascade of cellular events leading to mitochondria induced
apoptosis17. With this in mind, we hypothesized that mUB treatment would decrease
the number of cells undergoing apoptosis induced by juglone. Using the stain SYTO12, we found that mUB at the concentration of 10µM significantly reduced the number
of cells undergoing apoptosis (Figure 4). While the other two concentrations of
urolithins were not statistically significant at reducing the number of apoptotic cells,
there is a trend of apoptotic cell reduction.

In summary, urolithins have several different bioactivities described in the literature.
However, molecular mechanisms responsible for their efficacy have only been well
described for oncology models. Until this point, few mechanisms have been identified
that explains the efficacy in non-oncology related disease models. Using various in
vivo and in vitro experiments along with recent advances in proteomics, we have
identified that mUB induced overexpression of NU4LM and increased complex I
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activity may, in part, be responsible for the beneficial effects of mUB in a high
oxidative stress environment like those found in several diseases.
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2.0 Experimental
2.1 C. elegans Maintenance
Wild-type (N2) C. elegans were obtained from the Caenorhabditis Genetics Center
(CGC) at the University of Minnesota. Worm cultures were maintained on Nematode
Growth Medium (NGM) (1.7% Agar, 0.3% NaCl, 0.25% peptone, 1mM CaCl, 1 mM
MgSO4, 5mg/L cholesterol in ethanol, and 2.5 mM KPO4) in petri dishes at 20°C with
UV-killed OP50 E. coli as a food source. Age synchronous cultures were obtained by
standard hypochlorite method18. For mUB treatment, C. elegans were washed from
their plates with liquid nematode growth medium (0.3% NaCl, 0.25% peptone, 1 mM
CaCl, 1 mM MgSO4, 5 mg/L cholesterol in ethanol, and 2.5 mM KPO4) and
transferred to culture flasks containing UV-killed OP50 E. coli as a food source.

2.2 Cell Culture Conditions
SH-SY5Y (human neuroblastoma) cell lines were obtained from the American Type
Culture Collection (ATCC) and were maintained using high glucose (4.5 g/L)
DMEM/F12 supplemented with 10% heat inactivated FBS, 1% penicillin (100 U/mL)
and streptomycin (100 μg/mL) and incubated in 5% CO2 at 37°C. To harvest SHSY5Y, cells were trypsinized (0.25% Trypsin/ EDTA), centrifuged (1500 rpm for 5
min) and re-suspended in 10% DMEM/F12. Cell concentration was determined by
counting cells with a hemocytometer and viability was assessed by trypan blue
staining. Prior to starting experiments, all-trans retinoic acid (RA) was used to
differentiate SH-SY5Y for 7 days at a concentration of 10 μM while changing media
every 48 hours to ensure proper neurite growth and cell morphology19.
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2.3 C. elegans Stress Resistance Assay
An age synchronous culture of N2 (L2) worms in liquid NGM was split into five
culture flasks. The flasks were treated with methylated urolithin B at 1, 5, and 10 µM
and 0.05% DMSO control. The cultures were placed on a rocker and incubated for 24
hours. After incubation, the cultures were transferred to small Petri-dishes containing
NGM with 400 µM Juglone. Immediately after the worms were added to their
respective petri dishes, a baseline count was taken with a dissecting microscope. Then,
worms were counted every hour until no surviving worms were left.20 Dead worms
were characterized via lack of pharyngeal pumping.

2.4 Staining for Apoptotic Cells in C. elegans
An age synchronous culture of N2 (L2) C. elegans were washed from their plate with
liquid NGM. The culture was then split into five culture flasks and treated with the
mUB and solvent control to a concentration of 1, 5, and 10 µM and 0.05% DMSO.
The flasks were placed on a rocker and incubated for 24 hours. The cultures were then
incubated with 400 µM juglone for one hour; this compound induces oxidative stress
eventually leading to death. After which time, the cultures were washed three times
with PBS to remove the E. coli food source. The stain, SYTO-12, was added to a final
concentration of 33 µM.21 The worms were incubated for an additional thirty minutes
in the dark. After incubation, the worms were washed once in PBS and then
anesthetized with 3% sodium azide in PBS and mounted onto microscope slides.
Visualization of SYTO-12 stain was done under an EVOS microscope with an
excitation filter of 518 nm. At least 20 worms were photographed per experimental
group. Raw images were processed through ImageJ and pixel area was measured.
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2.5 C. elegans Culturing for Mass Spectrometry Analysis
C. elegans were cultured on 100 mm plates using standard laboratory procedures.
When the worms reach the L4 stage, the plates were washed with 5ml of PBS. The
solution was centrifuged gently at 1,000 X g for 5 minutes to form a pellet gently. The
pellet was washed three times with 1 mL of PBS to remove the E. coli food source.
After the final washing, the supernatant was removed, and the pellet was suspended in
lysis buffer and allowed to incubate on ice for 10 minutes. Next, the solution was
centrifuged at 16,000 x g for 10 minutes at 4 C to pellet genetic material and cellular
debris. The supernatant was removed and kept on ice until further processing.

2.6 Protein Digestion Aided with Pressure Cycling Technology (PCT)
Protein digestion was performed on C. elegans lysate according to the published
method with modifications13. After obtaining 500 µL of the lysate at 1 mg/mL, 80 µL
of 100 mM DTT and 200 µL of 50 mM ABC were added and incubated for 10 min at
95°C. After, 80 µL of 200 mM IAA was added to the samples, vortexed and
incubated at room temperature for 30 min in the dark. An ice-cold mixture of
methanol (0.5 mL), chloroform (0.25 mL) and water (0.25 mL) was then added to the
samples to concentrate the protein. Samples were vortexed and spun at 16,000x g for
5 min at 4°C followed by an ice-cold methanol wash off the pellet. The pellet was resuspended in 145 µL of 50 mM ammonium bicarbonate (pH 7.4), and 25 µL of TPCK
treated trypsin (1mg/mL) was added to achieve a 1:20 trypsin ratio. Samples were
transferred to MicroTubes (Pressure BioSciences Inc., South Easton, MA) and placed
into a Barocycler NEP2320-45k (Pressure BioSciences Inc., South Easton, MA) to
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perform PCT-aided digestion following a published method with modifications.
Pressure cycling was performed for 90 cycles at 50°C. Each cycle consisted of 50
seconds at 35,000 psi and 10 seconds at ambient pressure. Trypsin digestion was
stopped by adding formic acid to achieve a final concentration of 0.1% formic acid.
Samples were vortex and spun at 1000x g for 5 min at 10°C. The supernatant was
collected and transferred to 150 µL micro-inserts for analysis.

2.7 LC-MS/MS Analysis
LC-MS/MS analysis was done as previously described13. In brief, the analysis was
done on a Sciex 5600 TripleTOF™ mass spectrometer using a DuoSpray™ ion source
(AB Sciex, Concord, Canada). The mass spectrometer was coupled to an Acquity
UPLC HClass system (Waters Corp., Milford, MA, USA) using an Acquity UPLC
Peptide BEH C18 (2.1 X 150 mm, 300 Å, 1.7 µm) with an Acquity VanGuard precolumn (2.1 X 5 mm, 300 Å, 1.7 µm). The injection volume was 10 µL and the
amount of protein per injection was 30 µg. TOF detector mass calibration was
monitored by injecting trypsin-digested β-galactosidase peptides before and after the
samples were run. Chromatographic and mass spectrometric methods for both
standard information dependent acquisition (IDA) and (SWATH-MS) data
acquisitions are previously described.13

2. 8 Data Processing with Skyline and R Studio
SWATH-MS data was imported into Skyline (University of Washington) for analysis
of proteins. Peptides were selected for each protein followed by peak visualization and
curation as previously described.13 The area under the curves (AUCs) for each peak
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were exported for comparison and heatmap generation in R-Studio using the Pretty
Heatmap and Color Brewer Palettes packages.

2.9 Complex I activity in human neuroblastomas, SH-SY5Y
Complex I activity was measured in differentiated SH-SY5Y human neuroblastomas.
Cells were pre-treated with vehicle control or mUB at 1, 5, or 10 µM for 24 hours.
After which time, the cells were treated with 400 µM hydrogen peroxide for an
additional 24 hours. Cells were harvested and washed twice in PBS. Complex I
activity was then measured using a colorimetric complex I enzyme activity microplate
assay kit (Abcam), per the manufacturer’s instructions.
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Figure 1. Kaplan-Meier survival curves of C. elegans treated 400µM Juglone and
DMSO solvent control, 1, 5, or 10µM of mUB.
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Figure 2. Heat map of the proteins identified in the samples that belong to the
mitochondria proteome. Values are relative changes about the control. Orange
indicates no changes in relative protein quantity. Red indicates a decrease in relative
protein quantity and green indicates an increase in relative protein quantity.
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Figure 3. Complex I activity in human neuroblastoma, SH-SY5Y, treated with mUB at
1, 5, and 10 micromolar. Complex I activity is significantly decreased by hydrogen
peroxide treatment. mUB treatment rescued complex I activity from hydrogen
peroxide treatment.
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Figure 4. Percent Fluorescent signal of apoptotic cells after incubation with juglone
and treatment with mUB, or solvent control. Fluorescent microscopy images of C.
elegans. Staining using SYTO-12 for apoptotic cells. (A) C. elegans treated with
Juglone and 0.05% DMSO. (B) C. elegans treated with Juglone and 1µM mUB. (C) C.
elegans treated with Juglone and 5µM mUB. (D) C. elegans treated with Juglone and
10µM mUB.
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ABSTRACT
The biotransformation of ellagic acid by specific species gut microflora results in the
production of a group of compounds known as urolithins. The bioactivity of these
compounds has been studied in the context of multiple indications. One of the most
studied bioactivities is cancer where several therapeutic mechanisms of urolithins have
been proposed. However, recent research has identified that urolithins may also have
neuroprotective effects. As mechanisms responsible for the induction of cancerous cell
death are not likely to be responsible neuroprotection, we investigated possible
protein-urolithin interactions in a human neuroblastoma cell model. Using a
mechanism of action deconvolution method called drug affinity responsive target
stability (DARTS) we identified that the model compound, methylated urolithin B,
binds to the protein poly ADP-ribose polymerase-1 (PARP-1) and inhibits its activity
at nanomolar concentrations. This activity may help to explain the anti-cancer and
neuroprotective effects of urolithins as PARP -1 inhibitors are currently on the market
as cancer therapies and have gained attention in the current literature for potential their
application to neurodegenerative indications.
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1.0 Introduction
Urolithins are low molecular weight microbiota metabolites that have been studied in
relation to numerous indications1,2. Of these, the most notable is oncology where
urolithins have been studied regarding in vitro cancer cell viability3. Several
publications implicate molecular targets by which urolithins may exert an anti-cancer
therapeutic benefit4,5. However, recent reports suggest that some urolithins may have
neuroprotective effects6. Treatment with urolithins has been demonstrated to decrease
neuroinflammation and attenuate mitochondria dysfunction as induced by
aging7.While molecular targets of urolithins’ anti-cancer effects have been suggested,
the same targets are not likely to be responsible for the observed neuroprotective
effects. Urolithin induced cell-cycle arrest is observed at high concentrations, ~50 µM,
which is unlikely to be found in the brain. Therefore, we assert that molecular
mechanisms, distinctly different from those related to cancer, must exist to explain
urolithin’s neuroprotective properties.

Given this hypothesis, we chose to investigate molecular targets of methylated
urolithin B (mUB), a model compound, within human neuroblastoma, SH-SY5Y,
using drug affinity responsive target stability (DARTS). This technique is used for
identifying small molecules’ molecular targets. DARTS relies on the thermodynamic
stabilization of protein-ligand complexes and their resistance to protease degradation8.
After incubating SH-SY5Y cell lysate with mUB and a protease, SDS-PAGE is used
to determine differences in protein digestion, indicating a complex has formed
between a protein and mUB. We identified a band of protein protected from protease
digestion between 75 kilodaltons and 100 kilodaltons (Figure 1).
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The protein from the band of interest was extracted and eighteen peptides were
identified from the band (Table 1). Seventeen of these peptides corresponded to
proteins in the poly ADP-ribose family. Using the protein BLAST software tool
(NCBI, Bethesda, MD) it was identified that several of these peptides correspond to
conserved domains within the PARP family (Table 2). Given that PARP-1 is the most
represented protein in the band of interest, the molecular weight of the band of interest
most closely matches with PARP-1’s known molecular weight, and several of the
peptides identified are conserved within the protein family, we tentatively assigned the
identity of the protein band to be PARP-1. This initial identity from mass spectrometry
was then confirmed by a western blot (Figure 2). To further validate that PARP-1 is a
molecular target of mUB, PARP-1 activity was measured in the presence of activated
DNA, PARP-1’s endogenous target, and varying concentrations of mUB (Figure 3).
At low concentrations, 100 nM, PARP-1 activity was inhibited about 20% with an
increasing trend of inhibition with the highest concentration tested, 500 nm, inhibiting
about 30% of PARP-1 activity.

Further target validation comes from homology structure analysis. A structurally
similar compound, 6(5H)-phenanthridinone (Figure 4) is a known PARP-1 inhibitor
with an IC50 of 300 nM9. Despite mUB being a weaker inhibitor than 6(5H)phenanthridinone, a significant level of PARP-1 inhibition can be reached with
concentrations much lower than those commonly tested in in vitro and in vivo models.
With this in mind, it is important to consider the effect of PARP-1 inhibition when
investigating any efficacious effects of mUB. Given the highly conserved structure of
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urolithins, it is likely that many if not all of the urolithins can modulate PARP-1
activity. However, this has yet to been established and warrants future investigation.

As many groups have reported several different bioactivities of urolithins that are
fundamentally different than anti-cancer activity, we investigated alternative
mechanisms of action which might explain these reports. We found that the model
compound, mUB, is an inhibitor of PARP-1 which is implicated in several diseases
including cancer and neurodegenerative disease. These findings help to explain the
several different bioactivities of urolithins that have been reported.
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2.0 Experimental
2.1 Synthesis of methylated urolithin B
A previously published synthesis route was used for the synthesis of mUB10. The
identity of the compound was verified via high-performance liquid chromatography.

2.2 Cell culture and maintenance
Human neuroblastomas, SH-SY5Y, were purchased from ATCC (Manassas, VA) and
cultured using standard laboratory procedures. Cells were differentiated using all-trans
retinoic acid as previously described.11 Cells were harvested via trypsinization (0.25%
Trypsin/EDTA, Life Technologies, Grand Island, NY). After trypsinization, cells were
centrifuged at 1500 rpm for 5 minutes. Cells were then stored on ice until further
processing.

2.3 Drug affinity responsive target stability
DARTS was performed as described with modifications12. Briefly, SH-SY5Y cells
were lysed with M-PER (Thermo Fisher, Waltham, MA) on ice for 10 minutes
followed by centrifugation (1500 rpm for 5 minutes). The lysate was split into 99 µL
aliquots in 1.5mL centrifuge tubes. To one centrifuge tube, 1 µL of 50% DMSO was
added as a solvent control. To a separate centrifuge tube, 1 µL of 1,000 µM
methylated urolithin B in 50% DMSO was added to a final concentration of 10 µM
methylated urolithin B. The resulting mixtures were then incubated for thirty minutes
at room temperature with vigorous shaking. Each tube was split into three separate
aliquots in 1.5mL centrifuge tubes. To the tubes was added 2 µL of protease in a ratio
of 1:100 pronase:protein and the mixture was incubated for 15 minutes at room
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temperature. At that time, 2 µL of 20x protease inhibitor cocktail (Sigma-Aldrich, St.
Louis, MO) was added along with an equal volume of 2x Laemmli sample buffer
(Bio-Rad, Hercules, CA) and the samples were boiled for ten minutes. After heating,
samples were frozen at -80˚C until further processing.

2.4 SDS-PAGE
Pre-cast polyacrylamide gels (4-20% polyacrylamide gradient with ten 50 µL wells)
were purchased from Bio-Rad (Hercules, CA). Gels were placed into an
electrophoresis chamber and immersed in SDS running buffer (25 mM tris, 192 mM
glycine, 0.1% SDS). Gels were run at 24 mA until the loading buffer dye had reached
the bottom of the gel. Then, gels were fixed with a solution of 10% acetic acid, 25%
isopropanol, and 65% de-ionized water for 15 minutes. After fixing, gels were stained
with Coomassie Blue (10% acetic acid, 0.006% Coomassie Blue dye, 90% de-ionized
water) for two hours. Gels were then de-stained with 10% acetic acid until the protein
bands had become visible.

2.5 Protein Identification
Proteins were extracted from the polyacrylamide gel matrix as previously described
with modifications13. Briefly, protein bands were excised from SDS-PAGE gels with a
razor blade and placed into 1.5 mL centrifuge tubes. Bands were de-stained with 10%
acetic acid, with changes every 30 minutes, until the bands were completely destained. Then, disulfide bonds were reduced and cystine residues were alkylated with
dithiothreitol (DTT) and iodoacetamide (IAA) respectively. Gel bands were
dehydrated with acetonitrile for 10 minutes, after which time the solution was
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removed and the bands were lyophilized overnight. Then, gel bands were re-hydrated
on ice for 1 hour with a 10 µg/mL solution of trypsin in 25 mM ammonium
bicarbonate. Next, the excess solution was removed and the gel piece was covered
with 25 mM ammonium bicarbonate. The protein band/trypsin mixture was then
incubated overnight at 37°C. After incubation, the supernatant was collected and
placed into a 1.5 mL centrifuge tube. The gel band was washed with 20% acetonitrile,
1% trifluoroacetic acid, and 79% H2O for 1 hour while vortexing. The supernatant was
removed and added to the previous step’s supernatant. The combined fractions were
frozen at -80°C overnight and then lyophilized to dryness. Samples were reconstituted
in 50% acetonitrile/ 50% water and placed into HPLC sample vials until further
processing. The protein identity was determined using peptide mass fingerprinting
with a SciexTripleTOF 5600 mass spectrometer (Framingham, MA) using previously
described methods14.

2.6 Protein BLAST
Peptide sequences corresponding to the PARP protein family were analyzed via the
protein BLAST tool freely available from the NCBI (Bethesda, MD)
(https://blast.ncbi.nlm.nih.gov/Blast.cgi). FASTA peptides sequences were queried for
Homo sapiens proteins in the SwissProt database. The protein-protein algorithm was
used for sequence alignment.

2.7 Western blotting
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SDS-PAGE gels of cell lysate processed via the DARTS method were prepared as
described following standard laboratory procedures. Cell lysates were treated with
pronase at pronase:protein ratios of 1:1000, 1:500, and 1:100. Proteins were
transferred to a nitrocellulose membrane using a mini Trans-Blot transfer apparatus
(Bio-rad, Hercules, CA) at 100mA for 16 hours at 4°C. Membranes were removed
from the apparatus and blocked in 5% bovine serum albumin (BSA) for 1 hour at
room temperature. Then PARP-1 antibody (Abcam, Berlin, Germany), diluted in
blocking buffer, was applied to the membrane and allowed to incubate for 16 hours at
4°C. After several washes in TBST (137 mM NaCl, 2.7 mM KCl, 19 mM Tris Base),
primary antibody detection was carried out using a Vectastain Elite ABC kit (Vector
Labs, Burlingame, CA) as per the manufacturer’s instructions.

2.8 PARP-1 Inhibition
The inhibitory effect of mUB on PARP-1 activity determined with a PARP
homogenous inhibition assay kit (Trevigen, Gaitherburg, MD) as per the
manufacturer’s instructions. All tested mUb concentrations were performed in
triplicate.
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Figure 1. SDS-PAGE gel of SH-SY5Y cell lysate processed with the DARTS method
and stained with Coomassie Blue. Asterisks flank bands protected from digestion
which suggests a complex has been formed between mUB and the protein.
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Table 1. List of peptides identified in the protein gel band protected by mUB.
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Table 2. List of conserved protein regions for the 17 peptides identified as belonging
to the PARP family.
Name
PLN03124
PARP_Like
PARP
zf-PARP
PARP_reg

Accession
PLN03124
cd01437
pfam00644
pfam00645
pfam02877

Description
PARP; Provisional
PARP Catalytic Domain
PARP Catalytic Domain
PARP Zinc Finger Region
PARP Regulatory Domain
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E-value
7.77E-12
1.03E-11
7.68E-10
2.70E-04
2.84E-04

Figure 2. Western blot confirming that the identity of the protected protein band to be
PARP-1. The “-” indicates that pronase or mUB was not added to the reaction
mixture. The “+” indicates the addition of pronase or mUB to the reaction mixture. A
box surrounds the two bands which demonstrate that the addition of mUB protects
PARP-1 from pronase digestion. “+” = 1:1000, “++” = 1:500, “+++” = 1:100
pronase:protein ratio.
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Figure 3. Inhibition curve of mUB on PARP-1 activity.
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Figure 4. Chemical structure of mUB (Top) and 6(5H)-phenanthridinone (Bottom).
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CHAPTER 3

EFFICACY OF A PHENOLIC-ENRICHED EXTRACT OF MAPLE SYRUP IN A
MOUSE MODEL OF ALZHEIMER’S DISEASE
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ABSTRACT
In recent years, the role of inflammation in Alzheimer’s Disease pathogenesis and
progression has come to the forefront in the field. Several studies have suggested that
chronic inflammation, as a result of Alzheimer’s Disease pathology, can lead to
exacerbated disease progression. Therefore, targeting inflammation is a likely
therapeutic option. The sugar free, phenolic-enriched extract of maple syrup, known as
MSX, is a mixture of polyphenols and has been studied for safety, tolerability, and a
variety of different biological effects. Of these, MSX has shown to reduce
neuroinflammation in the human neuroblastoma cell line, SH-SY5Y. For these
reasons, this study investigated the efficacy of MSX in a transgenic mouse model of
Alzheimer’s disease and examine neuroinflammation as outcomes measure to
determine efficacy. We found that two doses of MSX were able to significantly
decrease the expression of several proteins related to inflammatory cascades and
phenotypic markers of innate immune cells that are thought to specifically respond to
Alzheimer’s disease pathology.

127

MANUSCRIPT 6
Manuscript 6 has been submitted to the journal of Nutritional Neuroscience

Anti-inflammatory effects of a food-grade phenolic-enriched maple syrup extract in a
mouse model of Alzheimer’s disease. Rose, Kenneth N.; Barlock, Benjamin; Liu,
Chang; DaSilva, Nicholas; Johnson, Shelby L.; Nelson, Robert; Fatemeh, Akhlaghi;
Seeram, Navindra P.

128

Abstract
Alzheimer’s disease (AD) is a growing global health crisis exacerbated by increasing
life span and an aging demographic. Convergent lines of evidence, including genomewide association studies, strongly implicate neuroinflammation in the pathogenesis of
AD. Several dietary agents, including (poly)phenolic-rich foods, show promise for the
prevention and/or management of AD, which in large part, has been attributed to their
anti-inflammatory effects. We previously reported that a food-grade phenolicenriched maple syrup extract (MSX) inhibit neuroinflammation in vitro but whether
these effects were translatable in vivo remain unknown. Here, we report that oral
administration of MSX (at doses of 100 and 200 mg/kg for 30 days) attenuates several
neuroinflammatory markers in 3xTg-AD mice, a murine model of amyloid and tau
pathology occurring in AD. Proteomics analysis by LC-MS/MS with SWATH
acquisition showed that 3xTg-AD mice dosed orally with MSX have decreased
expression of several inflammatory proteins, including, most notably, the AD riskassociated protein “triggering receptor expressed on myeloid cells-2” (TREM2), as
well as stimulator of interferon genes TMEM173, and suppressor of cytokine
signaling-6 (SOCS6). These data demonstrate that oral administration of this maple
syrup derived natural product reduces key neuroinflammatory indices of AD in the
3xTg-AD model of amyloid and tau pathology. Therefore, further studies to
investigate MSX’s potential as a dietary intervention strategy for AD prevention
and/or management are warranted.
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1.0 Introduction
The immune system is integral to the central nervous system (CNS). Having a major
role in brain homeostasis and brain development, the immune system, particularly
innate immunity, is necessary for proper brain function over an individual’s lifetime.
Under homeostatic conditions, many cell types with several different phenotypes work
in concert to survey the brain and regulate inflammatory responses. However, it is
thought that chronic diseases affecting the CNS dysregulate the immune system
function, which may in turn lead to exacerbated pathology1,2. For this reason,
inflammation has become an important target for neurodegenerative disease drug
discovery research.

Alzheimer’s disease (AD) is a chronic, neurodegenerative disease with a wellestablished connection to the inflammatory response3. The hallmark pathological
lesions in AD, amyloid-b plaques and neurofibrillary tangles, are associated with
dysregulation of central immune system function4. Recently, several groups have
reported that AD pathology involves a phenotypic switch of innate immune cells from
a homeostatic state to a neurodegenerative state5,6. Interestingly, after switching to a
neurodegenerative disease state, these cells lose their ability to regulate brain
homeostasis, a possible mechanism for how dysregulation of the innate immune
system can exacerbate pathology6. Studies investigating a potential molecular switch
for the shift between “homeostatic” and “neurodegenerative” phenotypes have
identified a signaling pathway that includes the proteins triggering receptor expressed
on myeloid cells-2 (TREM2) and apolipoprotein E (APOE) as key participants6. By
suppressing this signaling pathway, the investigators reported that a homeostatic
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phenotype could be restored. These findings suggest that suppressing
neuroinflammation and the TREM2-APOE pathway may have a beneficial therapeutic
effect against AD.

Evidence from genome-wide association studies (GWAS) has implicated variants in
the APOE and TREM2 genes with risk for AD. While the association between APOE
and AD has been established since the early 1990’s, variants of TREM2 and AD risk
have recently emerged. A clear genetic relationship exists between TREM2 and AD,
but the biological mechanism by which an increase in risk or protective effect occurs
is still unknown. With regard to other types of dementia, mutations in TREM2 leading
to its complete loss of function result in Nasu-Hakola disease (NHD), a rare disorder
leading to presenile dementia. There are many similarities between the brains of
patients with AD and NHD such as astrogliosis and immune cells in pro-inflammatory
states7. Furthermore, patients with NHD can develop AD-like pathology with
amyloid-b plaques and neurofibrillary tangles8. These findings demonstrate an
important connection between TREM2 induced dysregulation of the immune system
and the effects this can have on the brain.

Several attempts have been made to treat AD by regulating inflammation. For
instance, the non-steroidal anti-inflammatory drugs (NSAIDs), celexoxib and
naproxen, were evaluated for their effects on improving cognitive performance in
humans with AD. However, no statistically significant effects were observed with
NSAID treatment9. While GWASs have clearly identified the immune system as a
component contributing to pathology, the mechanisms by which this occurs are not
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fully understood. This lack of mechanistic understanding of AD has made drug
discovery efforts difficult. A potential method to circumvent this hurdle is to utilize
medicinal plant foods and their derived products, especially those rich in
(poly)phenolics which are known for their anti-inflammatory properties, as dietary
intervention strategies for AD prevention and/or management. In fact, several
phenolic-rich natural products including certain fruits, berries, spices, and green tea
have been reported to have beneficial effects against AD10–12. Recently, it has been
reported that polyphenol dietary supplements can improve deficits in cognition and
decrease arachidonic acid levels in the mouse model of AD, 3xTg-AD13–15.

Our group has conducted extensive chemical compositional studies on maple syrup, a
natural sweetener produced by boiling the sap of sugar maple (Acer saccharum) trees,
leading to the identification of over 60 phenolic constituents16–18. A phenolic-enriched
maple syrup extract was reported to decrease oligomerization and aggregation of both
Aβ1-42 and tau peptides19 In addition, our group reported on the antineuroinflammatory effects and anti-AD effects of a phenolic-enriched maple syrup
extract (MSX) in vitro and in Caenorhabditis elegans 20. However, to date, the
effects of MSX against AD has not been studied in any rodent models. Here we
sought to investigate whether MSX exerts anti-inflammatory effects using the 3xTgAD mouse model of AD.

GWAS and mRNA screening techniques have led to a deeper understanding of the
interplay between the immune system and AD. However, these techniques suffer from
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limited interpretation as genetic variants and mRNA do not perfectly correlate with
protein expression. As the functional component, monitoring protein expression is
preferred but often impractical. Here, we utilized sequential window acquisition of all
theoretical mass spectra (SWATH-MS), a data-independent proteomics method which
greatly improves upon the sensitivity and reproducibility of more traditional proteomic
approaches. SWATH-MS allows for the efficient and comprehensive characterization
of the inflammatory response at a protein level in response to pathology.
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2.0 Methods
2.1 Production of MSX
Details of the preparation and chemical standardization of a food grade phenolicenriched maple syrup extract (MSX) has been previously reported17. MSX contains
over 60 phenolic constituents present in the whole maple syrup food but with reduced
sucrose content. The extract is well tolerated with no toxicity observed at 1000 mg/kg
for 7 days in Sprague-Dawley rats17.

2.2 Mice
All female 4-week-old transgenic 3xTg-AD mice (The Jackson Laboratory, Bar
Harbor, ME) were used for all experiments. These mice harbor three familial
mutations of AD: (1) amyloid precursor protein (APP) KM670/671NL (Swedish). (2)
Microtubule associated protein tau (MAPT) P301L. (3) Presenillin-1 M146V. These
particular mice were chosen because they display intra-neuronal amyloid deposits
early in age, similar to the early stages of AD.

Mice were maintained in the University of Rhode Island’s mouse vivarium with a 12hour light/dark cycle with free access to food and water. Prior to treatment, mice were
acclimated for one week. Following acclimation, mice were treated for thirty days
with 100 mg/kg/day or 200 mg/kg/day MSX, or an equal volume of 0.5%
carboxymethylcellulose (CMC) as a solvent control via oral gavage five times per
week. Allometric scaling was used to choose doses of MSX which translate to a
reasonable dose in a human21. Based on this scaling method, the low and high doses
translate to 487.8 mg/day and 975.6 mg/day, respectively, for a 60 kg human. Each
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treatment groups consisted of six mice. One mouse in the 100 mg/kg/day MSX group
had to be euthanized per order of the attending veterinary due to hydrocephalus. An
additional five female C57BL/6 mouse brains, of the same age, were purchased from
BioIVT (Westbury, NY) to act as genetic background expression controls.

After thirty days of treatment, mice were anesthetized using an isoflurane chamber
(Patterson Scientific, Waukesha, WI). Mice were then euthanized via decapitation and
their brains removed and immediately stored on ice. Following removal, brains were
snap frozen in liquid nitrogen. After freezing, brains were stored at -80°C until further
processing. All protocols and procedures were approved by the University of Rhode
Island’s Institutional Animal Care and Use Committee.

2.3 Quantification of amyloid species
Sections of cortex or hippocampus were weighed out and placed into 2 mL screw cap
vials containing 1.4 mm ceramic beads (Omni International, Kennesaw, GA). Eight
volumes of 5 M guanidine-HCl in 50 mM Tris (pH 8.0) was added to the brain
sections. Brains were homogenized in a Bead Ruptor 24 (Omni International,
Kennesaw, GA). After which time the homogenate was shaken at room temperature
for three hours. Before amyloid analysis, the homogenate was diluted 10-fold with
PBS containing 1x protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO).
Quantification of amyloid was performed using an Amyloid beta 42 Mouse ELISA Kit
and Amyloid beta 40 Mouse Kit (ThermoFisher, Waltham, MA) following the
manufacturer’s instructions. Absorbance was read using a SpectraMax microplate
reader (Molecular Devices, San Jose, CA).
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2.4 Lipid Peroxidation Analysis
Brain lipid peroxidation was analyzed using a fluorometric lipid peroxidation (MDA)
assay kit (Abcam, Cambridge, UK). Brains sections from cortex and hippocampus
were weighed and homogenized in 150 µL of water and three µL BHT (supplied in the
kit). Samples were prepared in 2 mL screw cap vials containing 1.4 mm ceramic beads
and homogenized with a Bead Ruptor 24 (Omni International). Proteins were
precipitated with 153 µL of 2 N perchloric acid. The quantification of lipid
peroxidation from this prepared homogenate was performed following the
manufacturer’s instructions. Fluorescence was read using a SpectraMax microplate
reader (Molecular Devices, San Jose, CA).

2.5 Brain Tissue Preparation and Protein Digestion
Pre-weighed brain tissue was transferred to 2 mL screw cap vials filled with 1.4 mm
ceramic beads. Vials contained 7 volumes of pre-chilled homogenization buffer (50
mM Tris-HCl (pH 7.4), 0.5 mM EDTA, 0.25 M sucrose, and 20 µM BHT). Brain
tissue was then homogenized using a Bead Ruptor 24 (Omni International, Kennesaw,
GA). The resulting homogenate was centrifuged at 10,000 x g for 20 minutes at 4˚C.
Homogenate protein concentration was determined using a Pierce BCA protein kit
(ThermoFisher, Waltham, MA). Homogenate was diluted to 2.5 mg/mL using 50 mM
ammonium bicarbonate. Proper dilution was confirmed using a NanoDrop One/OneC
microvolume 9UV-Vis spectrophotometer to conserve sample (ThermoFisher,
Waltham, MA). Then, proteins were digested using a protein preparation kit and
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trypsin (SCIEX, Framingham, MA) along with pressure cycling technology (PCT) as
previously reported22.
2.6 Mass Spectrometry Data Acquisition with SWATH-MS
Mass spectrometry was performed as previously described with modifications22. Data
was acquired on a SCIEX TripleTOF® 5600 mass spectrometer using a DuoSpray™
ion source (SCIEX, Framingham, MA) coupled to an Acquity HClass UHPLC system
(Waters Corp., Milford, MA). An Acquity VanGuard pre-column (2.1 x 5 mm2, 300
Å, 1.7 µm) with an Acquity UPLC Peptide BEH C18 column (2.1 x 150 mm2, 300 Å,
1.7 µm) was used to achieve separation. The column temperature was set to 40˚C and
the autosampler was set to 10˚C. A linear gradient was used with a flow rate of 100
µL/min for 90 min. Mobile phase A consisted of 98% acetonitrile, 2% water and 0.1%
formic acid. Mobile phase B consisted of 98% water, 2% acetonitrile and 0.1% formic
acid. The gradient was as follows: 98% A from 0 to 5 min, 98% to 75% from 5 to 55
min, 75% to 50% A from 55 to 60 min, 50% to 20% from 60 to 70 min. Mobile phase
A was held at 20% from 70 to 75 min and returned to 98% A at 80 min. The column
was held at 98% A for 10 min to equilibrate prior to the next sample. A mixture of
trypsin-digested β-galactosidase peptides were used between every 10 samples to
calibrate masses and monitor the QTOF detector.

Positive ionization mode was used for SWATH data acquisition. The mass
spectrometer parameters are as follows: gas 1 60 psi, gas 2 60 psi, curtain gas 25 psi,
temperature 450˚C, ion spray voltage floating 5500 V, declustering potential 120,
collision energy 10 and collision energy spread 5. For data acquisition, a maximum of
50 candidate ions were monitored for each survey scan. All ions had a charge state
137

from 2 to 4. A range of m/z 300-1500 was used for exclusion criteria and all ions that
had an intensity greater than 25 cps were chosen for MS/MS analysis. The temperature
was set at 400˚C and the total cycle time was 3.95 sec. Seventy SWATH windows per
cycle were collected over m/z 400-1100 with each window size being m/z 10.

2.7 Mass Spectrometry Data Analysis
SWATH data was used for peptide and transition selections in Skyline (MacCoss lab,
University of Washington). The FASTA file for each protein to be analyzed (Table 1)
was imported into Skyline. Three surrogate, flyable peptides containing at least 3
transitions were selected and correlated with the other chosen peptides for each
respective protein. Peptide cutoff criteria included a minimum length of 6 and
maximum length of 25 amino acids and did not occur in the transmembrane domain,
did not contain posttranslational modifications or polymorphic variations. Peptide
selections were filtered down to two peptides per protein wherever possible. The
program MPPreport was used to calculate the total area under the curve for each
protein analyzed. Subsequently, transgenic animal protein expression was normalized
to wild-type animal protein expression.

2.8 Statistics
The statistical program Prism 7 (Graph Pad, San Diego, CA) was used for statistical
analysis and generation of figures. Comparing wild-type and untreated 3x-Tg-AD
protein expression was done with multiple, two-tailed t-tests with a a level of 0.05.
Two-way ANOVAs and Dunnett’s post hoc test were used to compare protein
expression across treated and untreated transgenic groups.
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3.0 Results
3.1 Early stage AD pathology induces changes in the expression of inflammatory
proteins in the brains of 3xTg-AD mice.
To better understand the nature of the inflammatory response at this stage of
pathology, the expression of inflammatory and AD-related proteins (Table 1) were
analyzed by SWATH-MS. Several inflammatory mediators were differentially
expressed in the cortex of 3xTg-AD mice as compared to wild-type mice (Table 2).
However, only two proteins were differentially expressed in the hippocampus (Table
3). These alterations in protein expression of inflammatory mediators and AD-related
proteins were then used as outcome measure for the possible efficacious benefit of
MSX supplementation.
3.2 Oral supplementation of MSX does not alter the generation of amyloid
species or the abundance of lipid peroxides
In addition to the expression of inflammatory mediators, lipid peroxidation and
pathogenic generation of amyloid species were evaluated as outcome measures to
quantify the potential efficacious benefits of MSX. No statistically significant
differences in lipid peroxidation levels were found between the cortex of untreated or
treated animals (untreated vs. low dose p=0.9998, untreated vs. high dose p=0.9993).
The same trend was identified in the hippocampus (untreated vs. low dose p=0.9821,
untreated vs. high dose p=0.2245) (Figure 1). The generation of Ab42 in the cortex was
not found to be statistically significant across groups (untreated vs. low dose
p=0.9999, untreated vs. high dose p=0.9978). Generation of Ab42 in the hippocampus
was slightly lower than the cortex, but generation did not change across treatment
groups (untreated vs. low dose p=0.1259, untreated vs. high dose p=0.1350) (Figure
2). Generation of Ab40 was also unchanged by MSX treatment (Figure 3) (Cortex:
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untreated vs. low dose p=0.9065, untreated vs. high dose p=0.9978) (Hippocampus:
untreated vs. low dose p=0.9995, untreated vs. high dose p=0.9942).
3.3 Oral MSX supplementation significantly reduces the expression of several
pro-inflammatory proteins correlated with AD in the cortex of 3xTg-AD mice
With MSX supplementations, several proteins related to AD were downregulated to
near wild-type expression levels (Figure 4). TREM2 (p=<0.0001), CD36 (p=0.0017),
ITGAX (p=<0.0001), and CSF1R (p=0.0005) were overexpressed in transgenic
animals compared to wild-type, and high dose (200 mg/kg/day) MSX reduced
expression to near baseline expression. Low dose (100 mg/kg/day) of MSX has a
similar trend to the high dose, with TREM2 (p=<0.0001) and CSF1R (p=0.0264)
showing reduced expression. In both the high and low dose groups, APOE expression
was unchanged (p=0.3798, p=0.3798 respectively).

The inflammatory mediators TMEM173 and SOCS6 were highly overexpressed in the
control treated 3xTg-AD mice compared to wild-type expression. Both the high and
low dose MSX treatments reduced TMEM173 (p=<0.0001, p=0.0036 respectively)
and SOCS6 (p=<0.0001, p=<0.001 respectively) expression to near baseline
expression (Figure 5).

The higher dose of MSX reduced the expression of proteins associated with AD and
inflammation associated innate immune cells. The expression of C1qa, while
unaffected by low dose MSX (p=0.2996) was significantly reduced by high dose MSX
(p=<0.0001). Furthermore, CTSB (p=<0.0001), CTSL (p=0.0021), and LPL
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(p=<0.0001) were also downregulated toward baseline expression with high dose
MSX treatment (Figure 6).

Several inflammatory mediators and AD related proteins analyzed were not shown to
have differential expression with either high or low MSX treatment. However, TNFA
(p=0.0007), SOD1 (p=0.0378), TLR4 (p=0.0217), and were upregulated with low dose
MSX treatment but not with high dose MSX treatment (p=0.0694, p=0.5334,
p=0.8886, p=0.9959 respectively) (Figure 7). High dose MSX reduced TIMP2
(p=0.0484) expression but these differences were not seen in low dose MSX
treatment. BACE expression was increased in both the high (p=<0.0001) and low
(p=0.0044) MSX groups.

3.4 Oral supplementation of MSX does not significantly alter the expression of
pro-inflammatory proteins in the hippocampus of 3xTg-AD mice
The hippocampus had minimal changes in protein expression across all of the proteins
analyzed (Table 4). However, SOCS6 was marginally overexpressed in wild-type
mice and high dose of MSX reduced its expression to below baseline expression
(p=0.0424). High dose MSX also reduced TIMP2 (p=0.0006) and FADD (p=0.0255)
expression in the hippocampus, but low dose MSX did not affect the expression of any
of these proteins (Figures 8-11).
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4.0 Discussion
There is a clear relationship between neuroinflammation and AD23–27. Evidence from
genome-wide association studies (GWAS), genome-wide expression studies (GWES),
and immunohistochemistry (IHC) on human AD tissue suggest that the immune
system is dysregulated in patients with AD28–32. Furthermore, dysregulation of the
innate immune system may be contributing to the pathology or progression of AD33,34.
Therefore, we sought to characterize the inflammatory response of the 3xTg-AD
mouse model using the proteomics technique SWATH-MS. Then, we evaluated the
effects of a phenolic-enriched extract of maple syrup, MSX, on the model’s specific
inflammatory response.

Dietary sources of anti-inflammatory compounds which may alter neuroinflammation
are plant polyphenols. Several phenolic-enriched plant extracts and isolated pure
compounds o have been studied in the context of inflammation and AD35–38. However,
in vitro research often induces inflammation with LPS, a ligand of toll-like receptor-4
(TLR4). While LPS produces robust and repeatable results, recent studies
investigating the immune response to AD pathology have demonstrated the
complexity and uniqueness of this response5. MSX has shown anti-inflammatory and
neuroprotective properties in vitro with LPS stimulation19. Therefore, we sought out to
evaluate these effects in an in vivo model of AD.

Early in pathology, the 3xTg-AD has several changes in the expression of
inflammatory mediators. At this stage of pathology, the cortex is the most affected
while the hippocampus had little to moderate changes in protein expression. We used
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a custom-made list of inflammatory mediators (Table 1) that have been implicated in
AD pathology and related inflammatory responses. The largest differences were seen
with TREM2, TMEM173, and SOCS6. Alterations in the expression of CSF1R,
ITGAX, and CD36 were also observed which was expected as these proteins have
been previously implicated in the AD immune response. Surprisingly, APOE was not
upregulated by pathology. Previous research suggests that APOE works in concert
with TREM2 to regulate innate immune cell phenotype fate, however we did not
replicate these findings. As expected, increases in pro-inflammatory proteins were also
observed. The complement protein C1qA, NOS2, MAPK8, LPL, and the cathepsins
CTSB and CTSL were all upregulated by 3xTg-AD pathology (Table 2, 3). These
changes in inflammatory mediators clearly establish that the 3xTg-AD model, even at
this early stage of pathology, has a significant inflammatory response in the brain.

While there were several significant changes to inflammatory mediators, alteration to
lipid peroxidation levels were not observed (Figure 1). Often used as a marker of cell
damage, lipid peroxidation levels correlate with pathology and age39,40. In these
relatively young animals, differences in lipid peroxidation may be too small to notice
significant differences. However, as expected with this model, Ab42 generation was
significantly higher than Ab40. Treatment with MSX did not alter generation of either
of these amyloid species (Figure 2,3). This suggests that any anti-inflammatory effects
of MSX are not due to differences in pathological generation of amyloid species.

Once the inflammatory response in the 3xTg-AD model was established with
SWATH-MS, we were able to evaluate the effects of MSX using alterations in the
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inflammatory response as outcome measures. The anti-inflammatory effects of MSX
were shown to be specific to the cortex. Given the age of the animals used and that in
this animal model, pathology begins in the cortex and appears in the hippocampus
later in life, therefore we expected minimal changes to hippocampal protein
expression41. After MSX treatment, the expression of several proteins that have been
implicated in AD pathogenesis were reduced (Figure 4). Particularly, CSF1R, a
promotor of microglia proliferation, was reduced to near basal expression. CSF1R
serves as an interesting topic as pharmacological inhibition of CSF1R has been shown
to reduce AD-like pathology in vivo42. Furthermore, the expression of CD36 was also
significantly reduced. CD36 has been identified as a risk factor for the development of
AD and has been demonstrated to associate with amyloid plaques and stimulate the
release of pro-inflammatory cytokines43,44. Similarly, the expression of ITGAX and
TREM2, markers of innate immune cells in a pro-inflammatory phenotype, were
reduced5,45. Together, these findings suggest that the phenotype of innate immune cells
in the brain has changed with MSX treatment. Given that these markers are associated
with a pro-inflammatory response, it is likely that the immune cell phenotype induced
by MSX treatment is associated with a reduction in inflammation. Interestingly, the
expression of APOE was unaltered by MSX treatment. Given previous findings that
suggest APOE and TREM2 work in concert to alter inflammatory phenotypes, this
result was unexpected. However, the animals used in this study are relatively young
and of a different genotype than previously researched models. Our data suggests that
at the endpoint of this study, APOE expression is not drastically overexpressed. It may
be possible that the pathology present in the 3xTg-AD mice at the endpoint of this
study do not elicit significant increases in APOE expression to notice differences in
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pharmacological modulation. Future research that analyses a longer time course of
MSX treatment and AD pathology progression is necessary.

The expression of two inflammatory mediators, TMEM173 and SOCS6, were
profoundly increased in control treated animals as compared to wild-type animals
(Figure 5). MSX treatment was able to reduce the expression of these proteins to near
baseline levels. TMEM173, also known as the stimulator of interferon genes, is a
potent initiator of an inflammatory response46. TMEM173 signaling leads to the
expression of type I interferons which further orchestrates an inflammatory response47.
Genetic knockouts of TMEM173 in models of murine prion disease reduced the
expression of inflammatory markers in the brain. While knockouts of type I interferon
slowed disease progression suggesting that limiting this signaling pathway may be
beneficial to attenuate neurodegenerative processes48. SOCS6 is a negative regulator
of receptor tyrosine kinase signaling that is overexpressed in the brains of patients
with AD49. Expression of SOCS6 can lead to mitochondrial dysfunction and apoptosis
through the BAX pathway50,51. Mitochondrial dysfunction is thought to play a role in
AD pathogenesis and/or progression52,53 . Taken together, the profound increase in
TMEM173 and SOCS6 in 3xTg-AD mice as compared to wild-type mice, and then the
dose dependent reduction in expression with MSX treatment suggest that MSX alters
inflammatory signaling. This provides further support that MSX alters the
inflammatory phenotype of innate immune cells in the brains in 3xTg-AD mice.

Recent work has suggested that a pro-inflammatory phenotype exist in the brains of
AD animal models which restrict homeostatic regulation. Therefore, limiting this
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phenotype may also confer a protective or therapeutic benefit to AD pathology. The
expression of several markers of these cells were significantly increased in the 3xTgAD mice which were then decreased by MSX treatment (Figure 6). In particular,
several cathepsins (CTSB, CTSL), C1qA, and LPL were shown to increase in
response to 3xTg-AD pathology. MSX treatment significantly reduced the expression
of these markers. These findings further provide evidence that MSX treatment shifts
the innate immune cell phenotype away from a pro-inflammatory state.

A select few inflammatory markers were upregulated with MSX treatment. The
expression of TNF-a and TLR4 was increased with low-dose MSX treatment but not
with high-dose MSX. In vitro experiments in murine microglia suggest that MSX
treatment reduces TNF-a levels, however our results do not replicate these finding20.
In addition to increases in TNF-a, the cell surface receptor, TLR4, was also increased.
This finding is not unexpected as TLR4 and TNF-a are part of the same signaling
pathway. TLR4 has been demonstrated to help coordinate an inflammatory response
against amyloid pathology54. It is possible that MSX may not act on pathways leading
to TLR4 expression resulting in increased TLR4 and through its signaling, increases in
TNF-a expression. Another unexpected result was a modest increase in BACE1
expression. BACE1 is a secretase responsible for the production of C99, the precursor
to beta-amyloid. However, this increase did not result in an increase in amyloid
generation of any species. More research is required to determine if this increase has
an effect on plaque pathology over the time course of the disease.
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Understanding the mechanism of MSX’s anti-inflammatory effects is complex. As an
extract, MSX contains several compounds, more than sixty of which have been
identified by our laboratory16–18, 55-57. The majority of compounds are lignans which
can act as phytoestrogens and may play a role in estrogen receptor signaling58,59.
Several other classes of polyphenols are also present which may contribute to the
reduction in inflammation through sequestration of radical oxygen species60. Our lab
group has isolated sufficient quantities of more than twenty of the compounds found in
MSX. When used in a C. elegans model of oxidative stress, only a few of the isolated
compounds were able to protect the worms from oxidative stress16. This suggests that
not all compounds found in MSX are active and that a synergy may exist between
several compounds which leads to the observed effects in this study. The use of bioassay guided fractionation or cheminformatics may be useful to better understand the
chemical constituents of MSX that leads to the reduction of AD neuroinflammation in
vivo. This topic is under current investigation by our group.
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5.0 Conclusion
The immune system has gained recent attention in the neurodegenerative research
field. Particularly in AD as several clinical trials with therapies aimed at the amyloid
hypothesis have failed to reach their clinical endpoints. The chronic inflammation as
seen in the human condition and recapitulated by animal models is thought to enhance
disease progression and may even be part of AD pathogenesis. Therefore, identifying
pharmaceutical agents that limit inflammation in the brain though practical routes,
such as oral administration, is of great importance and may lead to future clinical
trials. Herein, we have described an orally dosed extract of maple syrup (MSX) that
reduces neuroinflammation in the early stages of pathology in the 3xTg-AD model of
AD. By using advanced proteomic techniques, we monitored several proteins to
characterize the inflammatory phenotype in the brains of wild-type, untreated
transgenic, and treated transgenic mice with two different doses of MSX. Our results
demonstrate that MSX treatment may shift the innate immune system’s phenotype
away from an inflammatory state, potentially to a homeostatic state. However, more
research is required to rigorously phenotype these cells and how this change may
affect progression over the course of the AD.
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Table 1. List of proteins analyzed by LC-MS/MS with SWATH acquisition along with
ther abbreviations
Protein Abbreviation
CHIT1
CH3L1
CCL2
CD14
ITGAM
TNFA
IL1B
IL15
TNF10
CD36
BACE1
TNR11
TLR4
CD47
NLRP3
IRAK4
NOS2
SOD1
TMEM173
FADD
SHARPIN
SOCS6
APP
P2RY12
APOE
TCF4
TREM2
CST3
CSF1R
C1QA
TMEM119
CTSB
UFO
CTS7
CTSL
LPL
CSF1
LIRB4
TIMP2
ITGAX

Protein Name
Chitotriosidase-1
Chirinase-2-like protein 1
C-C motif chemokine 2
Monocyte differentiation antigen CD14
Integrin alpha-M
Tumer Necrosis Factor-alpha
Interleukin-1 beta
Interleukin-15
Tumer necrosis factor ligand superfamily member 10
Platelet glycoprotein 4
Beta-secretase 1
Tumer necrosis factor receptor superfamily member 11a
Toll-like receptor 4
Leukocyte surface antigen CD47
NACHT, LRR and PYD domains-containing protein 3
Interleukin-1 receptor accociated kinase 4
Nitric oxide synthase, inducible
Superoxide dismutase [Cu-Zn]
Stimulator of interferon genes protein
FAS-associated death domain protein
Sharpin
Supressor of cytokine signaling 6
Amyloid precursor protein
P2Y purinoceptor 12
Apolipoprotein E
Transcription factor 4
Triggering receptor expressed on myeloid cells 2
Cystatin-C
Macrophage colony-stimulating factor 1 receptor
Complememnt C1q subunit A
Transmembrane protein 119
Cathepsin B
Tyrosine-protein kinase receptor UFO
Catherpsin 7
Cathepsin L1
Lipoprotein lipase
Macrophage colony-stimulating factor 1
Leukocyte immunoglobulin-like receptor subfamily B member 4
Metalloproteinase inhibitor 2
Integrin alpha-x
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Table 2. Comparison of protein expression between wildtype mice and 3xTg-AD mice
in the cortex. Individual t-tests were used to determine statically significant
differences in protein expression between groups.
Protein Abbreviation

t ratio

Statistically Significant

Adjusted P-Value

CHIT1

2.805

No

0.2767

CH3L1
CCL2
CD14
ITAM

3.01
2.82
1.618
5.821

No
No
No
Yes

0.2229
0.2767
0.7013
0.0088

TNFA
IL1B
IL15

4.604
4.046
1.604

Yes
No
No

0.0316
0.0647
0.7013

TNF10
CD36
BACE1

2.164
5.572
3.477

No
Yes
No

0.4861
0.0102
0.1245

TNR11
TLR4
CD47
NLRP3

1.25
1.862
2.753
2.772

No
No
No
No

0.7013
0.5948
0.2767
0.2767

IRAK4
NOS2
SOD1

5.336
5.585
1.402

Yes
Yes
No

0.0131
0.0102
0.7013

TMEM173
FADD
SHARPIN

5.638
3.094
1.975

Yes
No
No

0.0101
0.2077
0.5642

SOCS6
APP
P2RY12
APOE

7.479
3.548
4.209
1.258

Yes
No
No
No

0.0015
0.1177
0.0532
0.7013

TCF4
TREM2
CST3

2.437
8.696
1.205

No
Yes
No

0.3683
0.0005
0.7013

CSF1R
C1QA
TMEM119

8.209
4.697
1.435

Yes
Yes
No

0.0007
0.0288
0.7013

CTSB
UFO
CTS7
CTSL

7.463
6.644
5.636
7.261

Yes
Yes
Yes
Yes

0.0015
0.0035
0.0101
0.0018

LPL
CSF1
LIRB4

3.661
4.752
1.592

No
Yes
No

0.1042
0.0277
0.7013

TIMP2
ITGAX

6.283
5.673

Yes
Yes

0.0052
0.0100
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Table 3. Comparison of protein expression between wildtype mice and 3xTg-AD mice
in the hippocampus. Individual t-tests were used to determine statically significant
differences in protein expression between groups.
t ratio

Statistically Significant

Adjusted P-Value

CHIT1

2.699

No

0.5356

CH3L1

1.221

No

0.9769

CCL2

2.411

No

0.6737

CD14
ITAM

1.373
3.725

No
No

0.9734
0.1571

TNFA

3.527

No

0.2026

IL1B
IL15

3.489
0.01164

No
No

0.2081
0.9986

TNF10

0.8633

No

0.9906

CD36
BACE1

1.904
7.581

No
Yes

0.8841
0.0014

TNR11

1.225

No

0.9769

TLR4
CD47

1.416
5.23

No
Yes

0.9724
0.0220

NLRP3

1.464

No

0.9701

IRAK4
NOS2

0.3198
1.078

No
No

0.9974
0.9769

SOD1

3.796

No

0.1456

TMEM173
FADD

1.557
0.2949

No
No

0.9646
0.9974

SHARPIN

2.097

No

0.8156

SOCS6
APP

2.26
2.538

No
No

0.7379
0.5956

P2RY12

0.8742

No

0.9842

APOE
TCF4

1.928
3.888

No
No

0.8732
0.1309

TREM2

0.04763

No

0.9986

CST3
CSF1R

2.798
1.306

No
No

0.4782
0.9690

C1QA

2.09

No

0.8156

TMEM119
CTSB

4.004
0.8642

No
No

0.1138
0.9842

Protein Abbreviation

UFO

1.871

No

0.8745

CTS7
CTSL

1.547
1.319

No
No

0.9582
0.9690

LPL

2.642

No

0.5455

CSF1
LIRB4

3.813
0.6078

No
No

0.1421
0.9842

TIMP2

1.141

No

0.9691

ITGAX

1.754

No

0.9099
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Figure 1. Abundance of lipid peroxidation is unaltered in the brains of 3xTg-AD mice
treated with MSX.
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Figure 2. Generation of Ab42 in the cortex and hippocampus is unaltered by MSX
treatment.
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Figure 3. Generation of Ab40 in the cortex and hippocampus is unaltered by MSX
treatment.
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Figure 4. Differential expression of AD related proteins in the cortex of 3xTg-AD
mice with MSX treatment. The dietary supplementation of MSX results in a dosedependent decrease in the expression of inflammatory mediators specifically
implicated in AD. Data shown as mean of all biological replicates with standard
deviation, *= p<0.05.
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Figure 5. Proteins highly overexpressed in untreated 3xTg-AD mice were significantly
reduced in the cortex of 3xTg-AD mice with MSX treatment. The dietary
supplementation of MSX results in a dose-dependent decrease in the expression of
inflammatory mediators which were drastically overexpressed as compared to control.
Data shown as mean of all biological replicates with standard deviation, *= p<0.05.
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Figure 6. MSX treatment results in the decrease of inflammatory mediators associated
with AD related pro-inflammatory immune cells. Markers of disease associated
immune cells were significantly reduced in a dose dependent manner with dietary
supplementation of MSX. Data shown as mean of all biological replicates with
standard deviation, *= p<0.05.
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Figure 7. Treatment with MSX resulted in minimal changes to several
inflammatory mediators. Several of the proteins analyzed were unaltered or
minimally altered by MSX treatment. Data shown as mean of all biological replicates
with standard deviation, *= p<0.05.

164

Figure 8. Treatment with MSX did not alter the expression of AD related
inflammatory mediators in the cortex. Supplementation of MSX did not result in
differential expression of inflammatory meditators. Data shown as mean of all
biological replicates with standard deviation, *= p<0.05.
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Figure 9. Proteins highly overexpressed in the cortex showed no changes in expression
as compared to wild-type mice or with MSX treatment. Data shown as mean of all
biological replicates with standard deviation, *= p<0.05.
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Figure 10. Treatment with MSX did not reduce the expression of pro-inflammatory
immune cell signatures in the hippocampus. MSX treatment did not result in
differential expression of inflammatory mediators associated with pro-inflammatory
immune cells. Data shown as mean of all biological replicates with standard deviation,
*= p<0.05.
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Figure 11. Dietary supplementation with MSX resulted in minimal alterations to the
expression pattern of several inflammatory mediators in the hippocampus. At this age,
wild-type mice and 3xTg-AD mice have similar expression patterns in the cortex.
MSX treatment had minimal effect on this expression pattern. Data shown as mean of
all biological replicates with standard deviation, *= p<0.05.
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CONCLUSIONARY REMARKS
Humanity has been exploiting the therapeutic and psychoactive effects of natural
products for thousands of years, however, the idea of drug hunting in natural products
is a relatively modern idea. Since the conceptualization of modern drug-discovery in
the early 19th century, natural products have served as the foundation on which many
medicines are built upon. In the case of Alzheimer’s disease, botanical natural
products may be particularly helpful in drug discovery efforts. Epidemiological
evidence suggests that higher dietary intake of botanical natural products, like those
from fruits, vegetables, and spices, is correlated with lower risk of developing the
disease. These findings suggest that dietary natural products have compounds intrinsic
to them which may be useful for the treatment or prevention of Alzheimer’s disease.

However, despite the strong epidemiological evidence, clinical trials aimed at treating
Alzheimer’s disease with natural products have been unsuccessful. These failures are
due, in part, to the difficulties of studying the disease. With a long pre-clinical stage,
rapid cognitive decline in the clinical stage, and poor methods for early detection and
diagnosis, establishing suitable inclusion/exclusion criteria and outcome measures to
evaluate a particular drug is a significant challenge. Compounding the difficulty of
clinical trials is the lack of understanding surrounding the disease biology. For decades
the main targets of drug discovery efforts were the pathological hallmarks of the
disease, amyloid plaques, and tau tangles. Despite the strong connection between the
appearance of these hallmarks and Alzheimer’s disease, therapeutics aimed at these
targets have found little success in the clinic. To overcome these challenges, a
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paradigm shift in the way Alzheimer’s disease is researched, and thereby treated, is
needed.

Currently, the Alzheimer’s disease research community is on the brink of this
paradigm shift. Instead of focusing on targeting and removing the pathological
hallmarks, the focus is starting to shift to systems ancillary to plaque and tangle
pathology. One of the main targets is neuroinflammation as it is thought to play a role
in disease progression. However, the neuroinflammatory response to disease is very
complex and it is not yet clear which mechanisms should be targeted to produce a
therapeutic benefit. To overcome this hurdle, a bottom-up approach can be used.
Instead of taking a critical part of disease biology, identifying a therapeutic
mechanism, and then exploit that mechanism pharmacologically, the bottom-up
approach is agnostic to therapeutic mechanism and may in turn discover therapeutic
mechanisms. One way to go about this approach is to treat animal models of the
disease that recapitulate the neuroinflammation that has been observed in the human
condition with extracts of natural products. These extracts would have a diverse
chemical makeup and therefore, likely act on multiple systems. Changes in
neuroinflammation can be monitored as outcome measures. Extracts that alter the
neuroinflammatory phenotype can then be further tested to elucidate the compound or
compounds responsible for the therapeutic effect, then the mechanisms of action of
these compounds can be identified. This method allows for the relatively efficient
screening of dozens of extracts containing several hundreds to even thousands of
individual constituents. Furthermore, this method may lead to new insights in disease
biology which may change how Alzheimer’s disease is treated.
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This dissertation is the beginning of the bottom-up approach that has established the
tools and methods required for this approach to be successful. The screening of a large
library of natural product extracts and pure compounds using wild-type and transgenic
Caenorhabditis elegans concluded in the identification of several extracts and natural
products that prolong the lifespan of these models when undergoing stress from a
toxin or one of the pathological hallmarks of Alzheimer’s disease. Investigations into
one of these compounds, a gut microbiota metabolite of a natural product, led to the
discovery of two mechanisms of action which potentially explain the observed
protective effects against Alzheimer’s disease pathology. And finally, investigations
into a natural product extract orally dosed in a transgenic mouse model of Alzheimer’s
disease led to the identification of two efficacious doses that significantly reduce early
neuroinflammation.

While Alzheimer disease drug discovery has been one of the greatest medical
challenges to date, recent work has given the research community a more refined
understanding of disease biology. With these revelations and the failures of many
major clinical trials focusing on pathological hallmarks of the disease, the field is
shifting to new hypotheses that may provide more insight into the disease and tractable
therapeutic routes. Botanical natural products and the gut microbiota metabolites of
natural products may provide a source of compounds which can be used to evaluate
several hypotheses and, with more research, be used therapeutically.
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